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1 Short Summary 
 
ScHARR has been commissioned by the UK National Screening Committee (NSC) to consider the cost-
effectiveness and endoscopy capacity requirements of a variety of different screening options incorporating 
faecal immunochemical testing (FIT) and bowel scope (BS) within the Bowel Cancer Screening Programme 
(BCSP). 
An existing cost-effectiveness model was used. The model was refined considerably, new data included and 
model validation was undertaken. All FIT thresholds between 20 and 180 µg/ml were modelled. Analyses were 
undertaken to determine which screening strategies involving repeated FIT screening and/or bowel scope are 
most cost-effective given endoscopy constraints.  
Note that the conclusions reached are based on optimising cost-effectiveness where effectiveness is measured 
in terms of QALYs gained. If the aim was to optimise QALY gains or CRC incidence/mortality reduction then 
conclusions would be different. 
The analysis without endoscopy constraints indicates that the most cost effective screening strategy is the one 
which delivers the most intensive screening.  Regardless of capacity constraints the current screening 
strategies (gFOBT 2-yearly 60-74 with or without bowel scope age 55) are dominated by a FIT screening 
strategy (i.e. a FIT strategy exists which is more effective and less expensive). 
For repeated FIT screening it is recommended that the screening interval is kept to 2-yearly screening. 
However, increased benefits may be obtained by re-inviting non-attenders after a 1 year interval. The optimal 
starting age for a repeated FIT screening strategy is 50 or 51 hence it is suggested that the screening start age 
is reduced compared to what is currently used in the BCSP. The optimal upper screening age varies between 
65 and 74, depending on the capacity constraint used. The optimal FIT threshold depends on the available 
capacity for screening referral colonoscopies. With 50,000 screening referral colonoscopies (current capacity) 
then we recommend a strategy of 2-yearly, age 51-65, FIT161 (8 screens).  With 70,000 screening referral 
colonoscopies (current capacity) then we recommend a strategy of: 2-yearly, age 50-70, FIT153 (11 screens). If 
90,000 screening referral colonoscopies is considered feasible to achieve in the future then we recommend a 
strategy of 2-yearly, age 50-74, FIT124 (13 screens). 
In terms of bowel scope screening the model found uncertainty in whether it is cost effective to replace one 
FIT screen with a one-off bowel scope at age 58/59. However, a repeated FIT screening strategy requiring  
125k screening referral colonoscopies annually would be far more effective and cost effective than a one-off 
bowel scope at age 59. ^ƵĐŚƐƚƌĂƚĞŐŝĞƐĐŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚƚŽŚĂǀĞĞƋƵŝǀĂůĞŶƚ ‘ĞŶĚŽƐĐŽƉǇĐĂƉĂĐŝƚǇ ? ?ĂƐƐƵŵŝŶŐ
that 10 bowel scopes and 4 screening referral colonoscopies are equivalent ).Hence, if bowel scope capacity 
could be used for undertaking screening referral colonoscopies this would result in higher effectiveness and 
cost-effectiveness. 
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2 Executive Summary 
 
Aim 
ScHARR has been commissioned by the UK National Screening Committee (NSC) to consider the cost-
effectiveness and endoscopy capacity requirements of a variety of different screening options incorporating 
faecal immunochemical testing (FIT) and bowel scope (BS) within the Bowel Cancer Screening Programme 
(BCSP). 
New data review 
Data was obtained from the BCSP in July 2016 which describes screening outcomes (uptake, positivity rates, 
false positivity rates, detection rates) for both guaiac faecal occult blood test (gFOBT) screening and bowel 
scope (BS) [1]. In addition data on computerised tomography colonography (CTC) usage was obtained. This 
data was analysed to explore changes over time and variations by demographic factors. 
Data was obtained from the FIT pilot [2]. FIT sensitivity and specificity data were incorporated within the 
model but unfortunately could not be incorporated within the model calibration as no age breakdown was 
available. BCSP and Office for Data Release (ODR) approval, a lengthy process, is required to obtain the data 
broken down by age so it is suggested that this data be incorporated within phase 2 of the work programme. 
Data on long term follow-up from the Nottingham gFOBT trial and the UK flexible sigmoidoscopy screening 
trial (UKFSST)  is available and was used for model validation [3].  
Data on endoscopy capacity was obtained from the BCSP, published literature and via discussions with experts 
(Matt Rutter and Neil Hawkes). 
Modelling Approach 
These phase 1 analyses utilise the existing ScHARR bowel cancer screening model from 2011. Although several 
model refinements have been made in the last 5 years the model had not been fully revised since 2011. Hence, 
the data informing all model parameters was reviewed and updated where appropriate including: cost data, 
utility data, screening test data (uptake, compliance, repeat testing) and mortality data. 
In addition to model updates several model refinements were also implemented: 
x Treatment costs in the model vary by age to represent differences in treatment pathways by age. 
x Utilities vary by age and cancer stage, to better incorporate quality of life differences between 
screening strategies targeted at different age groups.  
x Utility decrements for colonoscopy adverse events (bleeding and perforation) are included.  
x Follow up with CTC has been added to the screening pathways modelled, along with appropriate costs 
and referrals. 
x The incorporation of FIT screening for all test thresholds from 20-180 µg/ml. (Estimates of FIT 
screening characteristics were derived by fitting curves to data from the FIT pilot.) 
x The incorporation of FIT sensitivity which varies by screening round. 
The review and analysis of available data has confirmed the potential to produce a more sophisticated patient 
level model of bowel cancer screening with the currently available data. Phase 2 proposes a patient level 
model structure that will allow improved estimates of model outcomes to be generated. Exploratory analyses 
were undertaken to attempt to quantify the limitations of the existing modelling approach.  
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Model Calibration 
A process of model calibration is used to estimate adenoma/cancer development and progression rates and 
screening test characteristics. The data available to inform this process was reviewed following input from Prof 
Wendy Atkin. New data from the BCSP on gFOBT screening is available but is unsuitable for inclusion as the 
prevalent and incident data available does not include complete screening history information. New data from 
the BCSP on bowel scope screening in persons aged 55 is available to supplement the data from the flexible 
sigmoidoscopy screening trial. This data was used to estimate the bowel scope screening test characteristics. 
The data informing adenoma prevalence was reviewed with clinical input sought from Prof Wendy Atkin. 
Based on the available data the model calibration was not updated. 
Model validation 
The model was validated against several different studies as part of this project. 
This study produces predictions for FIT screening similar to those reported by Murphy & Gray (2015) [4].  
Validation against screening data with long term follow-up was undertaken using (1) long term follow up data 
from the Nottingham FOBT trial [3] and (2) 17 year follow-up from the flexible sigmoidoscopy trial results [5]. 
This concluded that model CRC incidence estimates are fairly accurate, whilst the accuracy of CRC mortality 
estimates is highly sensitive to the mortality data used in the model, due to a high level of change in CRC and 
other cause mortality rates over the past 30 years. 
Validation of surveillance colonoscopies found a significant discrepancy between model predictions and data 
from the BCSP. The surveillance model parameters are associated with significant uncertainty; specifically: 
 ‘ĂĚĞŶŽŵĂƌĞĐƵƌƌĞŶĐĞƌĂƚĞĨŽůůŽǁŝŶŐƉŽůǇƉĞĐƚŽŵǇ ?ĂŶĚ ‘ƉƌŽ ŽƌƚŝŽŶŽĨĂĚĞŶŽŵĂƐƌĞĨĞƌƌĞĚĨŽƌĂŶŶƵĂů ? ?-yearly 
ƐƵƌǀĞŝůůĂŶĐĞ ? ?dŚĞŝŵƉĂĐƚŽĨƚŚĞƐĞƵŶĐĞƌƚĂŝŶƚŝĞƐǁĂƐĞǆƉůŽƌĞĚďǇǀĂƌǇŝŶŐƚŚĞƐĞƉĂƌĂŵĞƚĞƌǀĂůƵĞƐŚŽǁĞǀĞƌƚŚŝƐ
uncertainty could not entirely explain differences between model predictions and BCSP data. This issue will be 
examined as part of more detailed surveillance modelling in Phase 2. As a result the model predicted 
surveillance colonoscopy estimates presented here should be treated with caution. 
Key challenges of validating against long term follow up data were identified. In addition to the characteristics 
of the study population changes in other cause mortality, colorectal cancer mortality, and colorectal cancer 
incidence over the follow up period are important. We note that the ScHARR model performed well in 
validation when compared to the recent validation of the CISNET model to the FS trial data.[6] 
Future Research: Phase 2 Aims 
Phase 2 will develop a more sophisticated patient level model to allow evaluation of further screening options 
such as alternative surveillance criteria and modalities, targeted screening uptake interventions, and patient 
level screening strategies. This phase will have two key aims: 
x To deliver a patient level model structure that is compatible with addressing anticipated future 
research questions. 
x To undertake an evaluation of different surveillance strategies including FIT for follow up and 
alternative surveillance stopping criteria 
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Analyses undertaken 
Cost effectiveness was evaluated by considering a cohort in who the proposed screening strategy is fully rolled 
out. Model predictions for expected cost-effectiveness were generated for a lifetime horizon for a cohort of 50 
year olds (corresponding to 2016 population). Model predictions for expected resource use were generated 
for a cross sections of ages by running a series of cohorts to comprise the whole 2016 population. The whole 
population was modelled to receive the current screening strategy (gFOBT 60-74 2-yearly) for previous years 
(pre 2016) then changing to the proposed screening strategy for future years (post 2016). We note that 
resource use will change over time as more rounds of the proposed screening strategy are completed. 
Analyses were undertaken to address the following question: 
x What screening strategies involving FIT and/or bowel scope are most cost-effective given endoscopy 
constraints?  
 
Endoscopy capacity within the BCSP comprises: screening referral colonoscopy, bowel scope and surveillance 
colonoscopy. There is considerable uncertainty in the model predictions of surveillance colonoscopy (see 
validation) and capacity for bowel scope and colonoscopy are different so this analysis focused on the number 
of screening referral colonoscopies. Three different constraints on the number of screening referral 
colonoscopies were considered:(1) no capacity constraints, (2) existing capacity constraints observed in the 
NHS BCSP ( approx.. 50,000); (3) an optimistic estimate of the future capacity constraints for the NHS BCSP 
(approx. 90,000). Strategies involving bowel scope, gFOBT or FIT were considered, as were strategies involving 
both bowel scope and FIT. To identify the most cost-effective strategy a willingness to pay of £20,000 per QALY 
was used. 
The impact of several model uncertainties were explored though sensitivity analyses including: discount rates; 
costs and utility values (e.g. cancer treatment costs); screening uptake rates; screening test characteristics; 
symptomatic presentation rates; and varying cancer risk by gender.  
 
Results 
It is essential for the reader to understand that the optimal screening strategy will vary depending on what 
outcome measure you consider. For example, the optimal screening strategy will vary depending on whether 
you choose to maximise NMB (cost effectiveness), QALYs (effectiveness), CRC incidence reduction or CRC 
mortality reduction. For example, QALY gains tend to be maximised by screening younger ages (as lives saved 
are associated with a longer life expectancy) whereas CRC incidence and mortality tend to see the maximum 
reductions when screening older ages (as disease is more prevalent in older ages). In this report we focus the 
results on screening strategies which optimise cost-effectiveness. 
The optimal age in terms of cost-effectiveness for a one-off bowel scope screen is 59. (Note that QALY gain is 
optimised at a younger age and incidence and mortality reduction is maximised at an older age.) The optimal 
age (in terms of cost-effectiveness) for a one-off FIT120 screen is 57 regardless of FIT threshold (20-180 µg/ml 
were considered). Comparing a one-off FIT20 and a one-off bowel scope, we see that bowel scope is the most 
effective but FIT20 is the most cost effective. However under analyses in which bowel scope uptake and/or 
sensitivity is increased (in line with the trial data), bowel scope was associated with much higher effectiveness 
and cost effectiveness than FIT20 
With no constraints on the number of screening referral colonoscopies the optimal repeated FIT screening 
strategy is: FIT20 annual ages 50-74. For a screening referral colonoscopy capacity of 50,000 (current)-
90,000(optimistic future) 2-yearly screening from age 50/51 is optimal. For higher levels of screening referral 
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colonoscopy capacity screening with a lower FIT threshold and a wider age range is optimal. With 50,000 
screening referral colonoscopies (current capacity) then we recommend a strategy of 2-yearly, age 51-65, 
FIT161 (8 screens). With 70,000 screening referral colonoscopies (current capacity) then we recommend a 
strategy of: 2-yearly, age 50-70, FIT153 (11 screens).  If 90,000 screening referral colonoscopies is considered 
feasible to achieve in the future then we recommend a strategy of 2-yearly, age 50-74, FIT124 (13 screens). 
Screening strategies combining bowel scope and FIT were considered. For a repeated FIT screening strategy, 
whether it is cost effective to replace one FIT screen with one-off bowel scope at age 58 is very uncertain. It 
depends on the level of screening referral colonoscopies and also varies in sensitivity analyses.  
We consider an assumption that 10 bowel scopes and 4 screening referral colonoscopies are equivalent (based 
on procedure time). A repeated FIT screening strategy with 125k screening referral colonoscopies would be 
considerably more effective (over 3 times) and cost effective (over 4 times) than a one-off bowel scope at age 
59 (290k bowel scopes, 9k screening referral colonoscopies). 
 
Conclusions 
Note that these conclusions are based on optimising cost-effectiveness. If the aim was to optimise QALY gains 
or CRC incidence/mortality reduction then conclusions would be different. 
The analysis without endoscopy constraints indicates that the most cost effective screening is intensive FIT 
screening (annual screening with FIT20, ages 50-74).  However, the most cost-effective feasible screening 
strategy differs according to the endoscopy capacity available. 
Regardless of capacity constraints the current screening strategies (gFOBT 2-yearly 60-74 with or without 
bowel scope age 55) are dominated by a FIT screening strategy (i.e. a FIT strategy exists which is more effective 
and less expensive). So, compared to the current gFOBT screening programme increased benefits could be 
gained(QALYs) by switching to a screening programme involving repeated FIT screening. 
For repeated FIT screening  it is recommended that the screening interval is kept to 2-yearly screening. 
However, increased benefits may be obtained my re-inviting non-attenders after a 1 year interval. The optimal 
starting age for a repeated FIT screening strategy is 50/51 hence it is suggested that the screening start age is 
reduced compared to what is currently used in the BCSP. The optimal upper screening age varies between 65 
and 74, depending on the endoscopy capacity constraint used. The optimal FIT threshold depends on the 
available capacity for screening referral colonoscopies. With 50,000 screening referral colonoscopies (current 
capacity) then we recommend a strategy of 2-yearly, age 51-65, FIT161 (8 screening episodes). With 70,000 
screening referral colonoscopies (current capacity) then we recommend a strategy of: 2-yearly, age 50-70, 
FIT153 (11 screens). If 90,000 screening referral colonoscopies is considered feasible to achieve in the future 
then we recommend a strategy of 2-yearly, age 50-74, FIT124 (13 screening episodes). 
In terms of bowel scope screening the model found there is some uncertainty in whether it is cost effective to 
replace one FIT screen with a one-off bowel scope at age 58/59. However, a  one-off bowel scope at age 59 
(290k bowel scopes, 9k screening referral colonoscopies) is considerably less effective and a cost effective than 
a repeated FIT screening strategy associated with 125k screening referral colonoscopies. Such strategies could 
be considered to have equivalent endoscopy capacity. Hence, if bowel scope capacity could be converted to 
screening referral colonoscopy capacity instead, it would result in far higher effectiveness and cost-
effectiveness to undertake repeated FIT only screening strategies. 
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3 Background 
Colorectal cancer (CRC) is the fourth most common form of cancer in the UK. According to Cancer Research UK 
(CRUK), 41,112 new cases were diagnosed in 2013 and there were 15,903 deaths in 2014; the most recent 
years for which data is available [7]. Screening for CRC has been carried out over the past decade through the 
Bowel Cancer Screening Programme (BCSP). Current screening practice is to invite all individuals aged 55 to a 
single bowel scope (BS) screen, followed by screening using the guaiac faecal occult blood test (gFOBT) every 
two years between the ages of 60 and 74 [8]. Bowel scope is a recent addition to the screening programme 
and is not yet fully available everywhere across the country. Individuals testing positive are referred to 
colonoscopy services for follow-up investigation. 
ScHARR has previously been involved in appraising CRC screening options using the ScHARR Bowel Cancer 
Screening Model. Previous work has included evaluating cost-effectiveness, cost-utility and resource impact of 
gFOBT and BS screening in different age groups [9], work which informed the DepartmĞŶƚŽĨ,ĞĂůƚŚ ?ƐƉŽůŝĐǇŽŶ
bowel cancer screening in England. A reappraisal of screening options, commissioned by the NHS Cancer 
Screening Programme was undertaken in 2011 using data from the BCSP and other sources to update the 
model and evaluate a range of screening strategies including gFOBT and the faecal immunochemical test (FIT), 
together with determination of the optimal age for once-only BS screening [10, 11]. 
FIT is a more sensitive and reliable, but also more expensive test for CRC than gFOBT, which produces a 
quantitative read-out of cancer risk depending upon the amount of blood detected. A cost-effectiveness 
evaluation of FIT versus gFOBT based on the ScHARR model has been recently carried out for the UK National 
Screening Committee [4]. This has concluded that FIT screening should produce health benefits and cost-
savings, and be highly cost-effective compared with gFOBT screening. However, it is unclear what the optimum 
strategy for FIT screening might be in the context of the BCSP in terms of targeted age, follow-up cut-off score 
and use of BS, particularly since there are constraints on endoscopy capacity that may prevent the most cost-
effective option from being utilised. 
The NSC has commissioned from ScHARR a piece of research to consider the cost effectiveness and endoscopy 
capacity requirements of a variety of different screening options incorporating FIT. This work uses an updated 
version of the existing ScHARR model to produce results and predictions specifically targeted to inform policy 
making, and aims to answer the following questions:  
x What combination strategies involving Bowel Scope and FIT are most cost-effective? 
x What FIT roll-out strategies are feasible considering endoscopy capacity constraints? 
This report also contains summaries of recent data from the BCSP and other sources containing information 
used in the modelling including: 
x Data from the BCSP on gFOBT uptake, positivity and cancer detection rates; changes over time and 
prevalent versus incident screening. 
x Data on CT colonography use within the BCSP.  
x Data on bowel scope uptake and outcomes within the BCSP.  
x Comparison of data from the recent English FIT pilot with Italian FIT screening data used in previous 
analyses. 
x Estimates of current endoscopy capacity based on data from the BCSP and the Cancer Research UK 
2015 report.   
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4 Data Review 
4.1 gFOBT data from the BCSP 
Data from the BCSP was obtained for gFOBT screening between 2011 and 2015 [1]. During this time period 
almost 20 million screening invitations were sent, of which over 11 million resulted in an adequate sample. 
Data was obtained by gender, age and whether prevalent (first time screened; may be first or subsequent 
screening invitation) or incident (screening episodes subsequent to first taking up a screening invitation). Data 
on age was combined into two year age groups, as normally individuals are invited for screening in even age 
years meaning that the numbers of individuals screened at odd ages is very small. 
gFOBT screening uptake 
Screening uptake has remained fairly constant over the past five years at an average of 57% of those invited. 
Uptake is lower amongst men than women with only 54% of men taking up an invitation versus 59% of 
women. Uptake tends to rise with age, peaking at age 68-69 then falling in individuals aged over 70, (Figure 1). 
The gender difference in uptake is more marked in the younger age groups, dwindling to zero in the 72-74 year 
old group. 
Figure 1: Uptake of gFOBT screening by age and gender between 2011 and 2015
 
Screening uptake is far higher in individuals who have previously been screened (86%) than those who have 
never been screened (29%). Mean prevalent uptake has slightly fallen between 2011 and 2015, whereas 
incident uptake has stayed roughly the same (Figure 2). This is unsurprising given that as the screening 
programme has progressed there have been increasing numbers of individuals who have turned down 
multiple screening invitations and are highly unlikely to agree to ever being screened. It is expected that 
prevalent screening uptake would reach a steady state if the screening programme were to carry-on with the 
same screening test for 14 years and there is a cohort of individuals who have been invited every two years 
between the ages of 60 and 74. Currently the programme has been going on for 10 years, but only four rounds 
of prevalent screening data are available out of the 7- ?ƚŽƚĂůĞǆƉĞĐƚĞĚƌŽƵŶĚƐŽǀĞƌĂŶŝŶĚŝǀŝĚƵĂů ?ƐůŝĨĞƚŝŵĞ ?  
Prevalent uptake by screening session for year 2014/15 is shown in Figure 3. The first time individuals are sent 
an invitation to screening, uptake is almost 50%. However, amongst individuals who did not attend their first 
screen, uptake is lower than 20%, and is reduced further to around 10% for individuals who are being invited 
to their third round of screening, having not taken up screening in either of the previous two rounds. At the 
end of four screening rounds there remain 34% of invited individuals who have never been screened, although 
this number is likely to diminish slightly following all 7-8 screening rounds that an individual is likely to 
experience in their lifetime. These findings confirm and extend the results of a published analysis of the first 
three BCSP screening rounds [12]. 
12 
 
Figure 2: Uptake of prevalent and incident gFOBT 
screening over time
 
Figure 3: Uptake of prevalent and incident gFOBT 
screening by screening session for year 2014/15
 
 
gFOBT positivity 
The proportion of screening samples showing abnormality (positivity) has remained fairly constant over the 
past five years at an average of 1.9%. Positivity is higher amongst men at 2.3% than women in whom positivity 
is only 1.5%, and this difference is fairly consistent with age (Figure 4). 
Figure 4: Positivity of gFOBT screening by age and gender between 2011 and 2015 
 
Individuals who have never been screened before are more likely to show a positive result than those with a 
screening history, and this increases with prevalent screening round (Figure 5). This is likely to be partly 
explained by the correlation between age and abnormality (Figure 4). However, given the evidence that those 
at higher risk of CRC including men and individuals from socioeconomically deprived backgrounds are less 
likely to attend screening [2, 13], it is possible that they may be over-represented in subsequent prevalent 
screening rounds compared with the first screening round. Generally, there is a trend for positivity to have 
reduced slightly over time in both males and females, with a slight exception for 2015 (Figure 6). This trend is 
unsurprising as the screening programme is increasingly screening individuals who have been previously 
screened and therefore are at lower risk of cancer.  
Figure 5: Positivity of prevalent and incident 
gFOBT screening by screening session for year 
2014/15 
13 
 
 
Figure 6: Positivity of gFOBT screening by gender 
over time 
 
gFOBT false positives 
Around 15% of individuals with positive gFOBT samples turn out to have no abnormality upon further 
investigation. In women the false positive rate is 19%, whereas in men only 12% of positive samples are later 
found to have no abnormality. In general false positive rates have been decreasing slightly over time (Figure 7). 
Figure 7: False positive rate for gFOBT screening by gender over time 
 
In general false positive rates diminish slightly with increasing age (Figure 8). False positives are also lower for 
prevalent screening rounds than incident rounds at each given age. The inverse correlation with the 
proportion of abnormalities in these groups is likely to occur due to differences in case-mix as after the 
prevalent screen true positives (part of denominator) will be removed but false positives will remain and be 
more likely to be picked up in subsequent incident screens. 
Figure 8: False positive rate for prevalent and incident gFOBT screening by age between 2011 and 2015 
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gFOBT detection rates 
Over the past five years of screening CRC has been detected in 0.12% of adequately screened samples after 
follow-up investigation, with high risk adenomas accounting for a further 0.14%. A higher proportion of all 
adenomas are detected in men compared with women, with men around twice as likely to be diagnosed with 
an adenoma after follow-up investigation (Figure 9). Detection rates have changed little over time, but have 
reduced slightly for CRC (not shown). 
Figure 9: Detection rate after gFOBT screening and follow-up investigation for colorectal cancer and 
adenomas of different risk levels by gender between 2011 and 2015. 
 
The detection of CRC and all risk categories for adenomas generally increase with age (Figure 10). The age 60-
61 group is anomalous with higher detection rates due to being composed of first time screened individuals 
only - prevalent screening rounds detect higher proportions of adenomas than incident rounds (Figure 11). 
This is unsurprising as following detection of an adenoma individuals will enter the surveillance programme 
and will no longer be invited to screening. 
Figure 10: Detection rate after gFOBT screening and follow-up investigation for colorectal cancer and 
adenomas of different risk levels by age between 2011 and 2015 
 
 
Figure 11: Detection rate after gFOBT screening and follow-up investigation for colorectal cancer and 
adenomas of different risk levels by prevalent or incident screening round 
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gFOBT data from other sources 
Kronborg 2004 [14]: The 17 year follow up following a programme of biennial gFOBT screening for ages 45-75 
in Denmark is presented in this study. A mortality reduction was seen however an incidence reduction was not 
observed. It is difficult to use this study as calibration or validation data because the gFOBT protocol used 
differs from the BCSP in England. 
Scholefield 2012 [3]: This study presents the Nottingham trial of faecal occult blood testing for CRC 20-year 
follow-up. At a median follow-up of 19.5 years there was a 13% reduction in CRC mortality (95% CI 3% to 22%) 
in the intervention arm despite an uptake at first invitation of approximately 57%. The CRC mortality reduction 
in those accepting the first screening test, adjusted for the rate of non-compliers, was 18%. Despite removing 
615 adenomas >10 mm in size from the intervention arm, there was no significant difference in CRC incidence 
between the two arms (Screened 3.0%, 2,279, N=76,059 vs. Control 3.1% 2,354, N=75,919). Note that a 
median of 19.5 years of follow-up would provide over 90% power to detect a 10% reduction in the 
intervention arm. Hence it may be plausible that a reduction in incidence of less than 10% occurred. A non-
significant reduction in incidence of 6% was found after adjusting for non-acceptance of the 1st test (without 
adjustment the reduction was 3%). The majority of subjects were offered 3-5 tests compared to 8 in the BCSP. 
It seems plausible that gFOBT screening could have an impact on CRC incidence as FU colonoscopy removes 
adenomas. This study has been used for model validation (see section 4.4) 
Mandel 1999 [15]: This trial from Minnesota reports 18 years of follow up of biennial gFOBT screening (>=1 
spot referred to colonoscopy) finding a 21% lower CRC mortality rate than the control group (rate ratio, 0.79; 
95% CI = 0.62 ? ? ? ? ? ?ĂŶĚĂŵĂƌŬĞĚƌĞĚƵĐƚŝŽŶŝŶƚŚĞŝŶĐŝĚĞŶĐĞŽĨƵŬĞƐ ?ƐƚĂŐĞĐĂŶĐĞƌƐŝŶƐĐƌĞĞŶĞĚŐƌŽƵƉƐŝŶ
comparison with the control group. Again it is difficult to use this study as calibration or validation data 
because the gFOBT protocol used differs from the BCSP in England. 
 
4.2 Bowel scope data 
BCSP Bowel Scope Data 
Bowel scope is currently being rolled out in the BCSP but roll out is very slow due to endoscopy capacity issues. 
Currently 65% of centres have started rollout with 100% expected to start by December 2016. However 
complete roll out to a centre can take over 3 years due to issue in both capacity and capacity training.  
Data from the NHS BCSP on bowel scope detection rates, completion rates and uptake was obtained [1]. This 
includes outcomes of the 108,390 bowel scope procedures adequately carried out up to 30 April 2016. Uptake 
has improved slightly since the McGregor report, and is now at 44% (45% of men versus 43% of women). Of 
those that undergo the procedure, 4.4% require further investigation with colonoscopy. Data from 2014/15 
indicates that twice as many men (6.0%) require follow-up than women (2.9%). 
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Detection rates for cancer and other abnormalities are much higher than seen with gFOBT screening, ranging 
from 0.14% with CRC to 1.4% with low risk adenomas. Data from 2014/15 shows that diagnostic rates for all 
abnormalities are higher in men than women, although the difference is less marked for cancer than for other 
abnormalities (Figure 12). 
Figure 12: Detection rates for colorectal cancer and adenomas of different risk levels following BS, by gender 
for 2014/15 
 
A report from McGregor and others analysed data from the first 14 months of the programme [16]. In this 
time, 21,187 invitations were sent with an uptake of 43.1%, which was lower than the uptake seen in the pilot 
(55%) and for the gFOBT screening programme (54%). A small but statistically significant gender difference in 
uptake was observed (45% of men versus 42% of women), together with a significant socioeconomic gradient 
ranging from 33% in the most deprived quintile, to 53% in the least deprived.   
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4.3 FIT screening data 
FIT has several advantages over the current gFOBT test [17]. The gFOBT test requires manual subjective visual 
analysis of test cards, making it vulnerable to errors and to backlogs caused by unexpected loss of staff, 
whereas FIT uses an automated process. Sensitivity of the gFOBT test is not only lower than that of the FIT 
test, due to its inability to detect very small concentrations of blood, but also varies according to the quality of 
the manufactured guaiac reagent. Furthermore, FOBT testing cannot distinguish between human blood and 
certain dietary components including animal blood and antioxidants, whereas the FIT test is highly specific for 
human blood. The FIT test also has the advantage of providing a quantitative read-out of cancer risk, 
dependent upon the amount of blood detected, whereas gFOBT testing provides only a positive or negative 
response. The low sensitivity and specificity of gFOBT testing has led to the NHS BCSP currently using a 
complex three step screening process, each requiring six samples from three separate stools for a definitive 
positive result. This screening process results in poor uptake; particularly amongst disadvantaged groups, with 
high drop-out of individuals at each step, thus potentially missing high risk individuals [18]. In contrast, 
screening with FIT can be achieved using only one stool sample, which is easier to collect than when using 
gFOBT.  
Previous iterations of the model have used data from Italy to estimate the sensitivity and specificity of FIT. FIT 
screening has been carried out in some regions of Italy for several years. The programme varies between 
region, but in general a cut-off of 100ng/ml is used and screening starts at age 50 [19]. An Italian ecological 
study found that areas where FIT screening programmes were active showed a 22% reduction in CRC- specific 
mortality [20]. The impact of FIT programmes on mortality was greater and took place earlier compared with 
available evidence on gFOBT-based screening programmes.  
A FIT pilot took place in two of the five English screening hubs between April 2014 and October 2014 (40,930 
FIT invitations) [2]. The pilot observed higher uptake with FIT compared to gFOBT (66.4% vs. 59.3%, OR 1.35, 
95% CI 1.33-1.38). The FIT Pilot showed improved engagement amongst sub-populations that have hitherto 
been resistant to screening including males, those from lower socioeconomic groups, and those who were 
previous non-responders. Overall, the odds ratio for uptake of a screening invitation was 1.35 (95% confidence 
interval 1.33 to 1.38), with values above one indicating a higher uptake amongst people offered screening with 
FIT. Amongst the most deprived quintile of people, the odds ratio for uptake was 1.37 (1.31 to 1.43), whilst for 
males it was 1.41 (1.36 to 1.45). Uptake by screening history is displayed in Figure 13; the largest increase in 
uptake was observed for previous non-responders, for whom uptake increased from 12.50% with gFOBT to 
23.87% with FIT; odds ratio 2.20 (2.10 to 2.29). 
Figure 13 Uptake for gFOBt and FIT by screening history. 
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The pilot observed a higher positivity rate with FIT (cut-off of 20 µg/ml) compared to gFOBT (7.83% vs. 1.73%). 
At this cut-off (the lowest used), the cancer detection rate was 0.27% with FIT and 0.12% with FOBT, giving an 
OR of 2.20 (95% CI 1.73-2.79). When considering all neoplasms the odds ratio for detection rates increased to 
5.05 (95% CI 4.72-5.41). Five different FIT cut-offs were considered in the FIT pilot. Cancer detection rates 
were always higher with FIT than for gFOBT: the detection rate at the highest cut-off of 180 µg/ml was 0.13%. 
The positivity at this cut-off was 1.52%. The next largest cut-off was 150 µg/ml, with a positivity of 1.78%; 
similar to that for gFOBT. At this threshold FIT had a higher detection rate and positive predictive value (PPV) 
of advanced adenomas and of all neoplasms. Detection rates for cancer and advanced adenomas for the cut-
offs considered, and for gFOBT, are displayed in Figure 14. In conclusion, FIT is likely to offer advantages over 
gFOBT due to higher uptake and increased detection rates. 
Figure 14 Cancer and advanced adenoma detection rates for gFOBT and by FIT cut-off. 
 
 
FIT risk scoring systems 
Screening with FIT results in a quantitative result. Hence there is the potential to personalise FIT screening by 
ǀĂƌǇŝŶŐƚŚĞƚŚƌĞƐŚŽůĚĨŽƌĚĞĨŝŶŝŶŐĂƉŽƐŝƚŝǀĞƌĞƐƵůƚ ?ĚĞƉĞŶĚĞŶƚƵƉŽŶƚŚĞŝŶĚŝǀŝĚƵĂů ?ƐĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ?ƐƵĐŚĂƐ
age, gender and ethnicity). There is an ongoing systematic review, the primary objective of which is to identify 
risk scoring systems which combine the FIT result for colorectal cancer (CRC) screening with other personal 
characteristics to decide who should be referred for follow-up, and to determine whether this performs better 
than regular screening using the FIT [21]. 
An existing study by Stegeman et al developed a multivariable risk model with the following factors: total 
calcium intake, family history, age and FIT result [22]. Adding risk based stratification increases the accuracy of 
FIT-based CRC screening and could be used in preselection for colonoscopy in CRC screening programmes. The 
analysis indicates that if colonoscopy was offered to the top 10% of high risk patients according to the risk 
score (risk positivity threshold of 0.19), rather than the top 10% according to the FIT test (FIT positivity 
threshold of 50ng/ml), then an extra 5 cases of colon cancer would be detected per 100 high risk individuals. 
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4.4 Endoscopy Capacity 
Current and Projected Endoscopy Usage 
A study commissioned by CRUK reports that endoscopy activity in 2013/14 was 1.7million of which 1.37m was 
due to symptoms requiring diagnosis or treatment, 260,000 was part of surveillance programmes and 60,000 
was part of the BCSP) [23]. The CRUK model forecasts 2.4 million procedures in 2019/20. This is a growth of 
44% or 6.5% per annum. By 2019/20 it is expected that screening will account for around 330,000 of the 2.4 
million total procedures. 
The most recent data from the BCSP indicates that endoscopy activity has already significantly increased 
within the screening programme, and that currently the capacity exists to perform 165,000 procedures 
annually, comprising 106,000 BS screening procedures, 47,000 gFOBT and BS follow-up procedures, and 
13,000 surveillance procedures (Table 1). 
Table 1: Estimate of the number and type of endoscopy procedures currently performed annually within the 
BCSP. Surveillance data from 2015/16, gFOBT data from 2015, BS data extrapolated from September 2016 
data. 
Type of Procedures Number of Procedures 
gFOBT screening referral colonoscopy 39,783 
gFOBT follow-up BS 1,896 
gFOBT follow-up partial colon. 475 
Total gFOBT follow-up 42,154 
BS screening 106,020 
BS screening referral colonoscopy 4,530 
Total BS 110,550 
Surveillance colonoscopy 12,642 
Surveillance BS 208 
Total Surveillance 12,850 
TOTAL COLONOSCOPY PROCEDURES 57,430 
TOTAL BOWEL SCOPE PROCEDURES 108,124 
TOTAL ENDOSCOPY PROCEDURES 165,554 
 
The increase from the 2013/14 figure of 60,000 procedures reported by CRUK is almost entirely due to the 
continuing roll-out of BS and this is projected to continue to 2019/20, but there has also been a small but 
steady increase in gFOBT follow-up procedures in the past few years, projected to reach about 60,000 in total 
by 2019/20 (Figure 15). This is partly due to changes in demographics, but CRUK have also taken into account 
using FIT instead of gFOBT in the BCSP. FIT roll-out would be projected to increase the number of follow-up 
endoscopies by 102,000 if a low positivity threshold was used. However, CRUK have estimated that increasing 
the FIT positivity threshold to detect a comparable number of individuals to that currently identified by gFOBT 
would bring this down by 96,000 to only 6,000 extra follow-up procedures, thus minimising the impact of 
changes to the screening programme.  
Figure 15: Endoscopy procedures performed within the BCSP between 2011 and 2015, with projected figures 
for 2019/20 from CRUK. 
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It is important to note that increases in screening will also lead to increases in surveillance colonoscopy if the 
current criteria for surveillance are maintained. CRUK estimates that screening will also lead to an increase in 
surveillance procedures of 37,000 by 2019/20, over one third of the 105,000 extra surveillance procedures 
predicted. This suggests that of the 700,000 extra procedures predicted for 2019/20 compared with 2013/14, 
the BCSP will be responsible for over 300,000 (270,000 through screening - predominantly BS, and 37,000 
through surveillance), with changing demographics and population health responsible for a further quarter of 
extra procedures and changes to referral guidelines and public awareness responsible for the rest. This may be 
an underestimate. Currently, BS coverage is 31% (personal communication from John Davy, October 2016), 
suggesting that when fully rolled out there could be as many as 342,000 BS procedures annually. Added 
together with the CRUK estimates for FIT follow-up and surveillance procedures, this could take the total 
number of endoscopy procedures within the BCSP to 440,000 per year. 
The CRUK estimates do not take into account potential reductions in symptomatic referrals due to screening 
programmes, as there is currently no evidence to support this, although in theory it would be expected to have 
some impact. There has also been suggestion that some capacity could be freed up by using FIT testing as a 
first line tool to help decide who to send for endoscopy following symptomatic presentation. This has not yet 
been approved by NICE and it is unclear how much it would alleviate capacity issues. However, both these 
factors could result in future demand outside of the BCSP being lower than predicted by CRUK. 
Predicted Increases in Endoscopy Capacity 
Rising demand has put pressures on endoscopy units and this projected increase in endoscopy usage assumes 
ability to meet future demands. However, without significant increase in capacity this seems unlikely. The 
CRUK report indicates that staff shortages are the biggest problem; lack of physical space used to be an issue 
but has been addressed in most places in recent years [23]. There is also an issue in some units with aging 
equipment whose replacement has been hampered by financial constraints. This suggests that endoscopy is 
already at full capacity and that any increase in procedures in the future, whether from the BCSP, from 
surveillance or from symptomatic pathways will require additional investment above and beyond the standard 
cost of endoscopic procedures. It is essential to take this into consideration when estimating the cost-
effectiveness of different screening strategies. 
Staff shortages seem to be caused by a variety of different problems including problems with staff training, 
recruitment and retention. Staff trained to perform procedures may be either consultant gastroenterologists 
or non-medical endoscopists (nurses). There is a limit to the number of endoscopies that can be performed as 
repetitive strain injury is common, so a reasonable maximum is considered to be 5 lists per week, 
21 
 
corresponding to 40-48 points of activity. BS takes only 20 minutes and is one activity point, whereas 
diagnostic colonoscopy at 40 minutes is worth two points, with therapeutic colonoscopy corresponding to 
between 3 and 6 points depending upon complexity (personal communication from Neil Hawkes). This means 
that a trained staff member could in theory perform up to 2,000 BS or 1,000 diagnostic colonoscopies per year. 
However, in reality many staff perform far fewer, particularly consultants who may only do two lists a week 
because of other commitments. 
Traditional endoscopist training takes 12-18 months during which time 150-200 training scopes must be 
carried out and the list numbers of the consultant trainer reduced by one third (personal communication from 
Matt Rutter). A pilot of a more rapid training programme for non-medical endoscopists has recently been 
carried out (personal communication from Neil Hawkes). In this programme, nurses are trained over a six 
month period in either BS or gastroscopy (an endoscopic procedure of the upper GI tract). So far 40 new 
trainees have been produced and if evaluation of the pilot is positive, another 160 training positions could be 
available over the next two years. According to Neil Hawkes it is unlikely that any significant increase in 
capacity will come from consultant trainees, therefore increases in diagnostic endoscopy are likely to come 
largely from the non-medical endoscopist trainees. 
In theory, 200 new trainees could provide an additional 400,000 BS procedures annually (Table 2), although 
some will train in gastroscopy instead, it is not known what proportion of the total this may be. Colonoscopy 
requires further experience and training, which some of the trainees (perhaps up to one third) would be 
expected to acquire. However, the reality is likely to be far less optimistic according to Neil Hawkes as it is 
unclear how large the pool of recruits may be, whether quality of recruits will diminish beyond the pilot and 
whether trainees are successfully retained in the workforce. Trainees are usually nurses already working in the 
field of endoscopy; widening the recruitment pool may mean that extra training is necessary to get staff to the 
required standard. Furthermore, increasing the number of endoscopists alone is not sufficient to increase staff 
capacity, as nurse and administration support is also needed, together with additional consultant support for 
complex therapeutic colonoscopies that will increase as a result of BS screening.  
Table 2: Maximum estimates of increase in endoscopy capacity over the next two years.  
 By end 2016 By end 2018 
INCREASES IN CAPACITY 
Max. Number new trainees 40 200 
Max. Number additional BS procedures 80,000 400,000 
If one third trainees go on to train further in colonoscopy: 
Max. Number additional BS procedures 53,333 266,667 
Max. Number additional diagnostic colonoscopies 13,333 66,667 
TOTAL PREDICTED CAPACITY  
If all trainees recruited, trained in BS and retained 
Number BS procedures 161,457 374,791 
Number diagnostic colonoscopies 70,763 124,097 
If only 50% trainees recruited, trained in BS and retained 
Number BS procedures 134,791 241,458 
Number diagnostic colonoscopies 64,097 90,763 
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To conclude, currently about 60,000 diagnostic colonoscopies are performed each year as part of the NHS 
BCSP; about 47,000 due to follow-up and 13,000 due to surveillance. In the most optimistic scenario 124,000 
diagnostic colonoscopies could be performed per year by the end of 2018. It was assumed that the ratio of 
follow-up to surveillance colonoscopies would be the same as currently observed in the BCSP (72% of 
colonoscopies are for follow-up,). Hence it is estimated that by 2018 there will be capacity to perform about 
90,000 follow-up diagnostic colonoscopies. 
Colonoscopy quality 
Post-colonoscopy CRC (PCCRC) rates have been proposed as a key quality indicator of a colonoscopy service. 
Several methods of calculating PCCRC rates have been published, with reported rates varying between 2.1% 
and 7.5%. In their study, Morris and others propose a standardised methodology which demonstrates a PCCRC 
rate within 3 years of colonoscopy of 8.6% in the English NHS between 2001 and 2007 [24]. PCCRC rates have 
fallen over time, with the three year rate dropping from 10.2% in 2001, to 7.3% in 2007. It is essential to have a 
standardised methodology in order for service quality to be measured. It is estimated that at least 75% of 
PCCRCs are missed or preventable, and therefore, together with improvements that have occurred since 2007, 
a rate as low as 1% should be achievable. Remaining PCCRCs may represent rare fast growing cancers and 
therefore be unavoidable. 
 
4.5 CT colonography 
CT colonography (CTC) is recommended for patients who require further investigation, either following 
gFOBT/FIT screening or symptomatic presentation, but who are unsuitable for colonoscopy. Contraindications 
for colonoscopy include a having significant cardiovascular or respiratory condition, being too frail to undergo 
standard laxative preparation, or previously having an incomplete colonoscopy [25], although the latter is not 
relevant to screening follow-up. There may also be some additional cases where CTC is preferred over 
colonoscopy. If cancer or abnormality is detected during an examination, then patients are often referred to 
colonoscopy for more in depth investigation and potentially therapeutic benefit. This is because patients 
considered too frail to undergo colonoscopy for follow-up screening may be offered it if cancer or high risk 
abnormality is suspected, as the risks may now be considered acceptable. If patients are identified with CRC 
and are too frail for colonoscopy, then contrast-enhanced CTC may be carried out to enable staging of the 
cancer, and a CT chest exam is recommended to check for potential spread of cancer into the lungs. It is 
important to note that patients who are extremely frail or unwell may not undergo any further investigation at 
all, particularly if the abnormality is deemed low risk. 
CTC use within the BCSP 
Data from the BCSP about CTC usage is available for 2011 to 2015 [1]. Published data indicates that within the 
BCSP, CTC was used following 2.3% of positive FOBT tests between 2006 and 2012 [26].  CTC usage has 
increased over time as a proportion of all follow-up investigation in the BCSP from 3.6% in 2011 to 5.0% in 
2015 (
Figure 16). This represents about 2,500 referrals a year. The proportion of individuals referred to CTC increases 
with age (Figure 17). This is as expected given that the likelihood of an individual having contraindications or 
being too frail to undergo colonoscopy increases with age. 
 
Figure 16: The proportion of all follow-up 
investigations in the BCSP that use CTC, over time 
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Figure 17: The proportion of all follow-up 
investigations in the BCSP that use CTC, by age for 
2014/15
 
 
The BCSP has only just started to record radiology outcomes therefore the false positive and detection rates 
for CRC and other abnormalities after CTC follow-up cannot currently be assessed. 
 
The use of CTC as a tool of further investigation following screening is expected to stay roughly where it 
currently is at around 5% (personal communication from Dominic Blunt), although actual numbers of 
individuals referred is likely to increase due to an increase in population size of the screen eligible cohort, and 
potentially due to use of different screening strategies that detect more individuals (i.e. use of FIT instead of 
gFOBT). In 2015 there were a total of 83,000 procedures carried out following screening and symptomatic 
presentation, but 150,000 are predicted for 2020 by Cancer Research UK (Figure 18) [23]. This is partly because 
CTC is now recommended instead of barium enema; a less effective imaging procedure with a fourfold higher 
false negative rate. BCSP cases therefore only represent a small proportion of these. However, within the BCSP 
CTC use varies considerably by screening centre (0.039% ?9.7%, IQR 0.80 ?3.1% for 2006-2012 [26]), with some 
units still not offering it, and others referring almost 10% of patients requiring further investigation, partly due 
ƚŽƉƌĞƐƐƵƌĞŽŶĞŶĚŽƐĐŽƉǇƵŶŝƚƐďƵƚĂůƐŽĚƵĞƚŽůŽĐĂůĐůŝŶŝĐŝĂŶƐ ?ĂƚƚŝƚƵĚĞƐƚŽƌŝƐŬǁŝƚŚĨƌĂŝůƉĂƚŝĞŶƚƐ ?
Figure 18: Actual and projected numbers of patients undergoing barium enema vs CTC. Figure obtained from 
Dominic Blunt  
.  
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5 Methods 
These analyses utilise the existing ScHARR bowel cancer screening model from 2011 [10, 11]. For this analysis 
the data informing all the model parameters has been updated where appropriate.  Several refinements to the 
2011 model were also implemented: 
x Treatment costs in the updated model now vary by age to represent differences in treatment 
pathways by age. 
x Follow up with CTC has been added to the screening pathways modelled, along with appropriate costs 
and referrals. 
x The model now incorporates FIT screening with different test thresholds. 
x The model now incorporates the variation of gFOBT sensitivity by screening round. 
5.1 Modelling perspective and population 
The modelling approach and data sources follow the NICE guidelines for technology appraisal [27]. Costs and 
QALYs were inflated to the current year and were discounted by 3.5%. A willingness-to-pay threshold of 
£13,000 is used. This threshold was chosen as recent research has suggested that this is the most appropriate 
threshold for the NHS to use [28]. 
In order to determine the most cost effective screening strategy a single cohort is model over a lifetime. This 
cohort has the same size at age 50 as the 2016 England population. When modelling this single cohort, to 
allow a fair comparison between screening interventions which commence at different ages, discounting starts 
at age 50, which is the youngest age at which screening intervention may be first offered. Using this approach 
we compare the relative expected lifetime costs and benefits of screening strategies when they are fully rolled 
out i.e. each individual is offered all screening rounds available in the strategy. 
We generate estimated endoscopy capacity for years 1-5 of the introduction of the new screening programme. 
In order to generate estimates of endoscopy capacity requirement for the screening strategies it is necessary 
for the model to make predictions which relate to the current and future population of England. Endoscopy 
capacity requirements in years one to five will be affected by (1) the changing age distribution over time. For 
example, there will be more 55 year olds in future years than in 2016 and (2) lower disease prevalence in 
subsequent years due to more cancers and adenomas being screen-detected in initial years. Hence we model a 
population of persons aged 45-80 with an age distribution of the 2016 England population for the remainder of 
their lifetime. This is implemented by generating predictions for a series of cohorts for ages 45,46, ? ? ? ? ?For 
ƚŚĞĐŽŚŽƌƚŽĨĂŐĞ ?Ă ?ŵŽĚĞůůŝŶŐƐƚĂƌƚƐĨƌŽŵĂŐĞ ? ?ďƵƚƚŚĞŶƵŵďĞƌŽĨƉĞƌƐŽŶƐŝŶƚŚĞĐŽŚŽƌƚĂƚĂŐĞ ‘Ă ?ŵĂƚĐŚĞƐ
that of the 2016 England population. For the ǇĞĂƌƐďĞĨŽƌĞĂŐĞ ‘Ă ?ǁĞŵŽĚĞůƚŚĞĐƵƌƌĞŶƚƐĐƌĞĞŶŝŶŐƐƚƌĂƚĞŐǇ
(biennial gFOBT 60- ? ? ?ƚŽƌĞƉƌĞƐĞŶƚƉĂƐƚƐĐƌĞĞŶŝŶŐĂŶĚĨŽƌƚŚĞǇĞĂƌƐĨŽƌĂŐĞ ‘Ă ?ŽŶǁĂƌĚǁĞŵŽĚĞůƚŚĞ
proposed new screening strategy to represent the future. We note that the current screening programme is 
bowel scope age 55 and biennial gFOBT ages 60-74 with the bowel scope currently rolled out to approximately 
30% of the population. When estimating expected resource use in years 1-5 we consider that we are changing 
from a strategy of gFOBT biennial ages 60-74 to the proposed strategy.  
 
Endoscopy capacity within the BCSP comprises: screening referral colonoscopy, bowel scope and surveillance 
colonoscopy. There is considerable uncertainty in the model predictions of surveillance colonoscopy (see 
validation) and capacity for bowel scope and colonoscopy are different so this analysis focused on the number 
of screening referral colonoscopies. 
 
To summarise to generate estimates of expected lifetime costs, benefits and Net Monetary Benefit (NMB) for 
a single cohort of age 50. We generate estimates of year 1 endoscopy capacity requirements using the whole 
population model run for the 2016 England population receiving the current screening in the past and the 
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proposed strategy in the future. To determine the optimal strategy we consider expected costs, benefits and 
screening referral colonoscopy requirements in year 1. 
 
  
5.2 Colorectal cancer natural history model 
The ScHARR model simulates colorectal cancer natural history using a set of calibrated parameters. 
Parameters were not recalibrated for this analysis and have not changed since the 2011 reappraisal therefore 
the methods behind calibration are described here in brief only. Further details can be found in Appendix A. 
Health States 
The existing ScHARR bowel cancer screening model is a state transition model that simulates the life 
experience of a cohort of 30 year old individuals in the general population of England with normal epithelium 
through to the development of adenomas and CRC and subsequent death. The model is composed of a series 
of health states ĚĞĨŝŶĞĚĂĐĐŽƌĚŝŶŐƚŽĂŶŝŶĚŝǀŝĚƵĂů ?ƐƚƌƵĞƵŶĚĞƌůǇŝŶŐŚŝƐƚŽůŽŐŝĐĂůƐƚĂƚĞ ?ZŝƐĚŝǀŝĚĞĚŝŶƚŽĞŝŐŚƚ
ŚĞĂůƚŚƐƚĂƚĞƐǁŚŝĐŚĚĞƐĐƌŝďĞƚŚĞƵŬĞƐ ?ƐƚĂŐĞƐ-D and whether or not the CRC has been clinically diagnosed: 
preclinical/clinical, whilst health states for low-risk and intermediate/high-risk adenomas as defined by the 
current British Society of Gastroenterology (BSG) guidelines for endoscopic surveillance following adenoma 
removal [29] are also included. dŚĞ “ŚŝŐŚƌŝƐŬĂĚĞŶŽŵĂƐ ?ŚĞĂůƚŚƐƚĂƚĞŝŶĐůƵĚĞƐƉĞƌƐŽŶƐǁŝƚŚĂƚůĞĂƐƚ ?ƐŵĂůů
ĂĚĞŶŽŵĂƐŽƌĂƚůĞĂƐƚŽŶĞĂĚĞŶŽŵĂŽĨƐŝǌĞAN ?Đŵ ?dŚĞ “ůŽǁ-ƌŝƐŬĂĚĞŶŽŵĂƐ ?ŚĞĂůƚŚƐƚĂƚĞŝŶĐůƵĚĞƐƉĞƌƐŽŶƐǁŝƚŚ
1-2 small  ?A? ?Đŵ ?ĂĚĞŶŽŵĂƐ ?dŚĞƐĞŚĞĂůƚŚƐƚĂƚĞƐĐŽƌƌĞƐƉŽŶĚƚŽƚŚŽƐĞƵƐĞĚƚŽĚĞƚĞƌŵŝŶĞĂŶŝŶĚŝǀŝĚƵĂů ?Ɛ
surveillance strategy, so this approach eases the modelling of surveillance. The health states and transitions 
included within the natural history model are shown in Figure 19. 
 
 
 
Figure 19: Diagram of Model Structure 
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Natural history model calibration method 
The probability of transition from one health state to another cannot be directly measured in the population 
and therefore must be calibrated against known data about CRC incidence, adenoma prevalence and screening 
outcomes. Model calibration uses the Metropolis Hastings (MH) algorithm in the methods described by Whyte 
et al [30]. The aim of the calibration is to obtain parameter sets whose predictions are close to the observed 
data.  
 
Some new data relating to screening outcomes has come available since the 2011 screening options 
reappraisal. However, for a variety of different reasons this was unsuitable to use for recalibration purposes. A 
description of the new data, how it compares to the old data and the reasons for not using it to update the 
model calibration are described in full in Appendix B. 
 
It is reasonable to assume that the rates of adenoma development and progression will not change over time. 
However, it is possible that symptomatic presentation rates may change over time (with increasing symptom 
awareness and access to diagnostics). This possibility was explored in a sensitivity analysis. 
 
A full list of parameters obtained through the 2011 calibration and used in the current analysis is shown in 
Table 3. 
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Table 3: Model calibration results: best fitting parameter set and 95% percentiles 
 
  
Mortality 
As CRC survival rates have been observed to increase over time the CRC survival data was updated for this 
analysis. CRC mortality at one and three years by age and stage of diagnosis was obtained from the 
International Cancer Benchmarking Partnership [31], which provides survival data for a range of cancer types 
in several different countries including the UK. Previously, this was combined with estimates of three and five 
year survival by stage from the National Cancer Intelligence Network (NCIN) [32]. However, NCIN estimates 
have not been updated, therefore more recent estimates of one and five year survival by stage from CRUK 
were used [7]. Five year survival by age and stage was estimated from one year data by assuming that the ratio 
of five to one year survival would not change by age. 
It was assumed that all those surviving for five years would no longer be at risk from CRC mortality. In the 
model, those diagnosed with CRC are split into fatal and non-fatal CRC health states according to the 
proportions given by the five year survival data. Those with non-fatal CRC are assumed to die only from other 
causes, whereas those with fatal CRC die at an age and stage-dependent rate calculated from the survival data.  
To model deaths from causes other than CRC, all-cause mortality rates were obtained from the interim life 
tables for the UK 2012-2014 from the Office of National Statistics [33]. These include deaths from CRC, and 
therefore other-cause mortality rates were calculated by subtracting the proportion of deaths due to CRC at 
Parameter
Maximum a posteriori estimate,    
(95% percentiles) 
Annual transition probabilities
Normal epithelium to LR adenomas - age 30   0.021     (0.020, 0.022)
Normal epithelium to LR adenomas - age 50   0.020     (0.019, 0.021)
Normal epithelium to LR adenomas - age 70   0.045     (0.029, 0.047)
Normal epithelium to LR adenomas - age 100   0.011     (0.005, 0.031)
LR adenomas to high risk adenomas - age 30   0.009     (0.007, 0.014)
LR adenomas to high risk adenomas - age 50   0.008     (0.006, 0.008)
LR adenomas to high risk adenomas - age 70   0.008     (0.008, 0.010)
LR adenomas to HR adenomas - age 100   0.004     (0.003, 0.010)
HR adenomas to Dukes A CRC - age 30   0.029     (0.004, 0.031)
HR adenomas to Dukes A CRC - age 50   0.025     (0.022, 0.026)
HR adenomas to Dukes A CRC - age 70   0.054     (0.050, 0.058)
HR adenomas to Dukes A CRC - age 100   0.115     (0.084, 0.118)
Normal epithelium to CRC Dukes A   0.00004     (0.00003, 0.00008)
Preclinical CRC: Dukes A to Dukes B   0.51     (0.50, 0.89)
Preclinical CRC: Dukes B to Dukes' C   0.69     (0.50, 0.70)
Preclinical CRC: Dukes C to Stage D   0.71     (0.59, 0.73)
Symptomatic presention with CRC Dukes A   0.04     (0.04, 0.07)
Symptomatic presention with CRC Dukes B   0.18     (0.12, 0.18)
Symptomatic presention with CRC Dukes C   0.37     (0.30, 0.39)
Symptomatic presention with CRC Dukes D   0.74     (0.65, 0.92)
Screening test characteristics
gFOBT Sensitivity for LR adenomas   0.009     (0.009, 0.010)
gFOBT Sensitivity for HR adenomas   0.124     (0.121, 0.125)
gFOBT Sensitivity for CRC   0.242     (0.233, 0.253)
gFOBT Specificity age 50   0.994     (0.991, 0.995)
gFOBT Specificity age 70   0.973     (0.972, 0.978)
FS Sensitivity for LR adenomas   0.219     (0.212, 0.229)
FS Sensitivity for HR adenomas   0.710     (0.685, 0.742)
FS Sensitivity for CRC   0.617     (0.612, 0.741)
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each age from all-cause mortality. Data on the proportion of deaths due to CRC was obtained from the Office 
of National Statistics (ONS), deaths by age, sex and underlying cause of mortality, 2014 [34]. Deaths due to ICD 
code C18 (malignant neoplasm of the colon) and C19-21 (Malignant neoplasm of rectosigmoid junction, 
rectum and anus) were included in the total for CRC deaths. This slightly overestimates the total numbers of 
deaths due to CRC as it includes anal cancer; however, this is a rare cancer accounting for only 1% of total 
cancer cases. Deaths due to CRC cancer were divided by the total number of death registrations in this period 
to obtain the proportion of deaths due to CRC and thereby other cause mortality rates. 
There is some mismatch between the data used to calculate mortality, as the CRC survival data, ONS death 
certificate data, life tables and the CRC incidence data used in the model all come from different years. CRC 
survival has improved dramatically in recent years due to treatment improvements, whilst CRC incidence has 
also changed, in part due to the BCSP. This means that there is some uncertainty in the estimates of current 
and particularly future CRC mortality. Further investigation of this issue was carried out as part of model 
validation and is reported in the following section. 
 
 
 
 
5.3 Model Parameters 
5.3.1 Costs 
Cost of screening programme 
Screening programme costs were taken from the existing ScHARR bowel cancer screening model, which used 
costings from the Southern screening hub [10]. Composite screening costs were inflated from 2008/09 values 
to 2014/15 values using the Hospital and Community Health Services (HCHS) pay and prices index [35]. 
The FIT cost-effectiveness analysis recently commissioned by the NSC uses an estimate of gFOBT and FIT 
screening costs derived from a more recent analysis of Southern screening hub costs from Katy Reed [4, 36]. 
These estimates are considerably lower than the ScHARR values, but it is unclear how the differences have 
arisen. Some extra costs were included in the ScHARR analysis such as costs of the telephone helpline and 
appointments for follow-up of positive results. A sensitivity analysis was performed in which the Reed values 
were used in place of the ScHARR values. Separate costs for normal or positive results were not stated in the 
FIT cost-effectiveness study and so were assumed to be the same. 
Table 4: Screening Costs derived from the Southern screening hub 
Procedure ScHARR Costing Analysis [10] Reed Costing Analysis [4] 
Previous Cost 
(2008/9) 
Inflated Cost 
(2014/15) 
Inflated Cost (2014/15) for 
sensitivity analysis  
Cost of gFOBT screen (non-
compliers) 
£2.03  £2.23 £0.83 
Cost of gFOBT screen 
(normal result) 
£3.36 £3.69 £2.03 
Cost of gFOBT screen 
(positive result) 
£6.41 £7.04 £2.03 
Cost of FIT screen (non-
compliers) 
£6.43 £7.06 £1.66 
Cost of FIT screen (normal 
result) 
£7.37 £8.09 £5.14 
Cost of FIT screen (positive £10.67 £11.71 £5.14 
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result) 
Cost of specialised 
screening practitioner 
appointment for positive 
results (gFOBT & FIT) 
£5.53 £6.07 £10.59 
Cost of BS screen excl. BS 
exam (non-compliers) 
£5.02 £5.51 NA 
Cost of BS screen excl. BS 
exam (not referred to COL) 
£6.01 £6.60 NA 
Cost of BS screen excl. BS 
exam (referred to COL) 
£14.84 £16.29 NA 
 
Cost of colonoscopy, bowel scope and CTC 
Evidence on the costs of colonoscopy and BS, with and without polypectomy is available from the 2014/15 
NHS reference costs [37]. Endoscopic procedures may be carried out as outpatient appointments or as day 
case appointments, but the ratio of outpatient procedures to day case procedures for screening follow-up is 
unknown. For cost purposes it is assumed that all endoscopic procedures are carried out as day cases, given 
that the total number of recorded outpatient procedures in the NHS reference costs is small.  
Table 5: Endoscopy Costs 
Procedure Cost  Code Source 
Specialised Screening Practitioner following 
gFOBT of FIT 
£32.50 10.4 Unit Costs of Health and Social 
Care 2014/15 [35] 
Specialised Screening Practitioner following 
BS 
£16.25 10.4 Unit Costs of Health and Social 
Care 2014/15 [35] 
Diagnostic Colonoscopy £518  FZ51Z NHS Reference Costs 2014/15 [37] 
Diagnostic Colonoscopy with Biopsy £600 FZ52Z NHS Reference Costs 2014/15 [37] 
Diagnostic Bowel Scope  £430 FZ54Z NHS Reference Costs 2014/15 [37] 
Diagnostic Bowel Scope with Biopsy £484 FZ55Z NHS Reference Costs 2014/15 [37] 
Histopathology and Histology £29 DAPS02 NHS Reference Costs 2014/15 [37] 
 
Polypectomy will always involve a biopsy. It is unclear whether the NHS reference costs for endoscopy include 
the pathology costs associated with biopsy. For the purposes of this analysis we assume that pathology cost 
will be incurred on top of the procedure costs. The NHS reference cost for histopathology is £29 and this cost 
has been used in the model for both cancer and adenoma. The mean number of adenomas requiring 
pathology is assumed to be 1.9 based on data reported from the National Polyp Study by Winawer et al [38]. 
In 2014 ScHARR updated the reappraisal using current endoscopy costs. The study concluded that costs were 
ŝŶĨĂĐƚƐŝŵŝůĂƌďƵƚŝƚŝƐŝŵƉŽƌƚĂŶƚƚŽĚŝĨĨĞƌĞŶƚŝĂƚĞďĞƚǁĞĞŶ P ‘Bowel scope ĐŽƐƚ ? ? ‘dŽƚĂůƐĐƌĞĞŶŝŶŐĐŽƐƚƐ ?ĂŶĚ
 ‘^ĐƌĞĞŶŝŶŐĐŽƐƚƉĞƌƐĐƌĞĞŶŝŶŐĂƚƚĞŶĚĞĞ ? [39]. 
Data from the BCSP for 2014/15 indicates that CT colonography is used instead of colonoscopy as a first line 
follow up for on average 4.5% of screening patients testing positive in the initial screen [1]. The proportion of 
individuals referred for CTC increases with age from 3.2% of individuals aged 60-61 to 6.1% of individuals aged 
between 72 and 74. The age-dependent proportion of individuals referred to CTC was incorporated into the 
model as shown in Table 6. 
Table 6: Age-dependent referral to CTC as a proportion of total referrals for 2014/15 from the BCSP 
Age Total Diagnostic Test Referrals Total CTC Referrals Proportion CTC Referrals 
60-61 8,087 255 3.2% 
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62-63 8,222 304 3.7% 
64-65 8,877 399 4.5% 
66-67 9,380 415 4.4% 
68-69 8,106 381 4.7% 
70-71 6,668 354 5.3% 
72-74 6,819 414 6.1% 
TOTAL 56,159 2,522 4.5% 
 
NHS Reference Costs 2014/15 state the costs of Computerised Tomography scanning of one, two, three or 
more than three areas [37]. In line with a recent Health Technology Assessment [40], a cost of £135 relating to 
CT scan of more than three areas has been used in the model. 
 
Cost of treating screening complications 
The cost of treating a perforation due to colonoscopy, BS or CTC was assumed to be £1,273 from 2014/15 NHS 
reference costs (weighted mean of major large intestine procedures, 19 years and over) [37]. The cost of 
treating hospitalised bleeding following flexible sigmoidoscopy or colonoscopy was assumed to be £475 
(weighted mean of gastrointestinal bleed with multiple interventions, single intervention or without 
interventions). Both complications were assumed to be treated as non-elective short stay procedures. 
Lifetime costs of treating colorectal cancer 
The lifetime costs of treating CRC ďǇĂŐĞĂŶĚƵŬĞƐ ?ƐƚĂŐĞĂƚĚŝĂŐŶŽƐŝƐǁĞƌĞƚĂŬĞŶĨƌŽŵƚŚĞWZhƌĞƉŽƌƚŽŶ
early awareness interventions for CRC [41], which estimated costs using a CRC whole disease model [42]. Costs 
were inflated from 2012/13 to 2014/15 using the Hospital and Community Health Services (HCHS) pay and 
prices index [35]. Costs are shown in Table 7. 
Table 7 ?ŽƐƚƐŽĨƚƌĞĂƚŝŶŐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌďǇĂŐĞĂŶĚƵŬĞƐ ?ƐƚĂŐĞŽĨĚŝĂŐŶŽƐŝƐ ? ? ? ? ? ? ? ? ?
Age at diagnosis ƵŬĞƐ ? ƵŬĞƐ ? ƵŬĞƐ ? ƵŬĞƐ ? 
40-49 £8,865 £8,851 £14,672 £11,853 
50-59 £5,784 £7,104 £9,814 £8,550 
60-69 £4,682 £5,419 £7,351 £6,591 
70-79 £3,218 £3,498 £4,542 £4,420 
80-100 £1,397 £1,566 £1,580 £818 
 
The costs reported above were chosen to be the base case in the analysis due to being relatively recently 
estimated (thereby incorporating recent developments in treatment) and due to their stratification of costs by 
age as well as stage. Including age stratification is particularly important when assessing the differential cost-
effectiveness of screening strategies that differ between age groups.  
There are several other sources of CRC treatment costs. Firstly, the FIT cost-effectiveness analysis recently 
performed by Murphy & Gray uses a set of much higher, stage but not age-specific costs that are inflated from 
the ScHARR 2011 screening options reappraisal [10, 11]. These costs were originally produced for a 2009 
report on the costs and benefits of bowel cancer service developments [43] (Table 8). These costs are much 
higher than the costs reported in Table 7. 
A second set of costs were derived from the recent INCISIVE report [44], which estimates costs of treating a 
range of different cancers. Composite costs of CRC treatment by stage were estimated assuming costs 
excluded diagnostic costs (which are costed separately in the model), but included costs of treatment for 
relapse. The incisive report does not state the sources and years from which its unit costs are derived, so it was 
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assumed that all costs were from 2012/13. For the model analysis, costs were inflated to 2014/15 using the 
HCHS pay and prices index [35]. These costs are fairly close in value to the age and stage dependent costs 
shown in Table 7. A third set of CRC treatment costs are reported in a recent costing analysis from Hall et al 
(2015) [45] ?dŚŝƐƐƚƵĚǇƌĞĐŽƌĚĞĚĐŽƐƚƐĨŽƌ ? ?ŵŽŶƚŚƐĨŽůůŽǁŝŶŐĚŝĂŐŶŽƐŝƐŽĨ ? ? ?ƉĂƚŝĞŶƚƐǁŝƚŚƵŬĞƐ ? ?Žƌ
stage CRC. These costings were not used in sensitivity anĂůǇƐŝƐĂƐŶŽƵŬĞƐ ?ĐŽƐƚŝŶŐǁĂƐƌĞƉŽƌƚĞĚĂŶĚ
individuals were not representative of CRC patients as those who died or relapsed were excluded from the 
analysis. They fall between the INCISIVE and Murphy & Gray costs in magnitude. 
Finally, Laudicella and others have recently published a costing study using population based, patient level 
data to estimate the costs of treating four different types of cancer, including colorectal cancer, in each year 
following diagnosis [46]. The study is limited in that it groups early stage (Dukes A & B) and later stage (Dukes 
C & D), and groups individuals aged 18-64 or 65+, rather than providing data on a wider range of ages. 
However it has the advantage in that it reports costs for up to nine years following diagnosis which should 
include most costs of relapse. These costs differ from the others presented above in that they include all 
healthcare costs incurred by individuals and not those specifically incurred through colorectal cancer 
treatment. This has the advantage that healthcare costs indirectly attributed to cancer are included (for 
example extra care required to treat unrelated conditions in individuals with cancer), but the disadvantage 
that completely unrelated healthcare costs that would also be incurred in individuals without cancer are also 
included. The study does not estimate healthcare costs in individuals without cancer as comparison, but does 
estimate healthcare costs for the three years prior to cancer diagnosis. This means that cancer-related 
healthcare costs over the nine years following diagnosis could be estimated by subtracting the three-years pre- 
diagnosis costs from the costs for each year post-diagnosis (Table 8).  It was assumed that all diagnostic costs 
would be incurred in the year prior to diagnosis and therefore would not be included in the estimates. Year 2-9 
costs were discounted by 3.5% and the total over years 1-9 was inflated to 2014/15 values. Overall, year one 
only costs are slightly less than Murphy & Gray costs, whilst year 1-9 costs are much higher than any of those 
discussed previously, which is likely to be due to including indirect costs over the nine year time horizon. It is 
also notable that the reduction in CRC treatment costs in older age groups in the EEPRU cost estimates is less 
evident in the Laudicella year 1-9 estimates, particularly for early stages, which may indicate that whilst older 
individuals incur fewer direct treatment costs than younger individuals, they may incur more indirect cancer 
costs. 
Table 8 ?ůƚĞƌŶĂƚŝǀĞƐŽƵƌĐĞƐŽĨĐŽƐƚƐŽĨƚƌĞĂƚŝŶŐĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌďǇƵŬĞƐ ?ƐƚĂŐĞŽĨĚŝĂŐŶŽƐŝƐ, all inflated to 
2014/15 values. 
 ƵŬĞƐ ? ƵŬĞƐ ? ƵŬĞƐ ? ƵŬĞƐ ? 
Murphy & Gray Costs £13,469 £18,532 £25,416 £27,796 
INCISIVE Costs £3,768 £8,357 £13,554 £12,089 
Hall Costs £9,303 £12,373 £16,969 Not Supplied 
Laudicella Costs (<65 Yr1) £15,577 £20,115 
Laudicella Costs (65+ Yr1) £14,556 £15,885 
Laudicella Costs (<65 Yr1-9) £31,218 £44,086 
Laudicella Costs (65+ Yr1-9) £32,377 £37,371 
 
Given the large variation between CRC treatment costs estimates from different studies, sensitivity analysis 
was performed using the INCISIVE costs. Note that for simplicity the model implements all CRC treatment costs 
in the first year following diagnosis. 
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5.3.2 Screening test characteristics 
Screening test characteristics (sensitivity and specificity) were calculated from screening detection rates and 
estimated underlying disease prevalence. Estimates of test sensitivity and specificity were assumed to not vary 
by age.. 
In phase 2, this method will be updated to incorporate age, gender, location and cohort differences where 
data allows. Adenoma prevalence varies by gender and there is also evidence that screening test 
characteristics also vary by gender.[47] 
 
For consistency it is important that the populations for the screening data are the same with respect to age 
distribution, gender, and screening history. In this analysis detection rates and test characteristics were 
estimated for persons aged 60 who had not been previously screened. 
 
/ƚŝƐŝŵƉŽƌƚĂŶƚƚŚĂƚƚŚĞĂĚĞŶŽŵĂĐůĂƐƐŝĨŝĐĂƚŝŽŶĚĞĨŝŶŝƚŝŽŶƐƵƐĞĚĂƌĞƚŚĞƐĂŵĞ ?/ŶƚŚŝƐĂŶĂůǇƐŝƐ ‘ŚŝŐŚƌŝƐŬ
ĂĚĞŶŽŵĂƐ ?ĂƌĞĚĞĨŝŶĞĚƚŽďĞƚŚŽƐĞĚĞĨŝŶĞĚĂƐŝŶƚĞƌŵĞĚŝĂƚĞ ?ŚŝŐŚƌŝƐŬŝŶƚŚĞ^W PŚŝŐŚ-ƌŝƐŬĂĚĞŶŽŵĂƐ P ?A? ?
ĂĚĞŶŽŵĂƐŽƌA? ?ĂĚĞŶŽŵĂƐĂƚůĞĂƐƚŽŶĞŽĨǁŚŝĐŚǁĂƐA䠃?Đŵ ?ŽƌŝŶƚĞƌŵĞĚŝĂƚĞ-risk adenomas: (3 ?4 small 
ĂĚĞŶŽŵĂƐŽƌĂƚůĞĂƐƚŽŶĞA? ?Đŵ ? ? /ŶƚŚŝƐĂŶĂůǇƐŝƐ ‘ůŽǁƌŝƐŬĂĚĞŶŽŵĂƐ ?ĂƌĞĚĞĨŝŶĞĚĂƐ persons with 1-2 small 
(<1cm) adenomas. 
 
It is important that the populations considered are from the same setting (i.e. trial or pilot) as 
trial/observational populations may have different underlying prevalence and/or detection rates. For this 
analysis data from the NHS BCSP was considered for gFOBT, FIT and BS. In addition, these data were compared 
to other data from the literature including the UKFSST, and the Italian flexible sigmoidoscopy trial. 
 
 
Estimated disease prevalence 
Estimates of underlying disease prevalence were taken from the ScHARR model calibration. [30] 
 
Table 9: Disease prevalence estimates from the model calibration 
 
 
As colonoscopy has a very high sensitivity colonoscopy screening data is also useful to estimate disease 
prevalence. Data from the German colonoscopy screening programme (over 1.2 million persons in the 55-64 
age group) found similar disease prevalence to the above estimates). [47] 
 
Table 10: Detection rates in the German colonoscopy screening programme 
 
 
FIT and gFOBT data 
&Žƌ&/dƚŚĞĂŶĂůǇƐŝƐƵƐĞĚƚŚĞƐƵďŐƌŽƵƉ “WƌĞǀĂůĞŶƚƌŽƵŶĚŽĨĨŝƌƐƚƚŝŵĞŝŶǀŝƚĞĞƐŽŶůǇ ?ĨƌŽŵƚŚĞ&/dƉŝůŽƚ ?dŚŝƐ
subgroup is assumed to consist of persons aged 60 who have not previously been screened. 
 
Disease prevalence from model calibration
 Age  Low risk adenomas 
 High risk adenomas 
(intermediate of high 
risk BCSP classification) 
 Undiagnosed CRC  No adenomas or CRC 
55            34% 3.0% 0.3% 63%
60            37% 3.7% 0.5% 58%
65            39% 4.0% 0.7% 56%
Sex, Age, and Birth Cohort Effects in Colorectal Neoplasms. A Cohort Analysis, 2010
Detection rates (mean and 95%Cis)
Ages 55-64 Colorectal Cancer Any Advanced Neoplasm (iAdvanced adenomas HR adenomas (estimated)
Men 0.77% (0.75%,0.79%) 8.07% (8.00%,8.14%) 7.30% (7.23%,7.37%) 5.45% (5.39%,5.51%)
Women 0.39% (0.37%,0.40%) 4.35% (4.30%,4.39%) 3.96% (3.92%,4.01%) 2.96% (2.92%,3.00%)
Men and Women 0.55% (0.53%,0.56%) 5.91% (5.86%,5.95%) 5.36% (5.32%,5.40%) 4.00% (3.97%,4.03%)
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Data was available for five FIT thresholds (20, 40, 100, 150, 180). A power curve was fitted to the detection 
rates to allow estimation of detection rates for all FIT thresholds between 20 and 180. The power curve had 
the best fit of several models considered for both HR adenoma detection rate and false positive rate for both 
the subgroup and the whole FIT pilot population. There is a large degree of uncertainty in the FIT CRC 
detection rates, as the number of persons with cancer is just 6. (Note even when considering the whole FIT 
pilot data set there is still considerable uncertainty with just 73 cancer cases.) Figure 20 shows the data and 
fitted curves for the detection rates. 
 
Note for FIT20-FIT100 and bowel scope the sensitivity for HR adenomas is higher than sensitivity for CRC. This 
was also observed for the bowel scope both in the UKFSST and the BCSP data sets. Clinical opinion may find 
this observation to be implausible; however, it is consistently supported by the data. 
 
Figure 20: Detection rates and false positives from the FIT pilot: fitted curves 
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Table 11: Estimated detection rates and test characteristics from the FIT pilot by FIT threshold
 
 
Data on gFOBT screening is also available from the BCSP. This data set consists of over 445,000 
adequately screened 60 year olds. 
 
 
In the 2011 screening options appraisal [10, 11] only one FIT threshold was modelled through calibration 
(20µg/g), due to a lack of data on other thresholds. However, results from the English pilot allow for the 
incorporation of multiple thresholds within the economic evaluation. In the recent FIT cost-effectiveness 
analysis by Murphy & Gray (2015) [4], which used data from the FIT pilot [2] to calculate FIT sensitivity and 
specificity at each FIT screening cut-off. We note that our method results in much lower estimates for test 
FIT pilot: Age 60, first screen
FIT threshold
LR adenoma 
detection rate
LR adenoma 
sensitivity
HR adenoma 
detection rate
HR adenoma 
sensitivity
CRC detection 
rate
CRC sensitivity False positives Specificity 
20 0.22% 0.01 1.56% 0.42 0.17% 0.33 4.70% 0.920
25 0.22% 0.01 1.39% 0.38 0.15% 0.30 3.78% 0.935
30 0.22% 0.01 1.27% 0.34 0.14% 0.28 3.17% 0.946
35 0.22% 0.01 1.17% 0.32 0.13% 0.27 2.73% 0.953
40 0.22% 0.01 1.09% 0.30 0.13% 0.25 2.40% 0.959
45 0.22% 0.01 1.03% 0.28 0.12% 0.24 2.14% 0.963
50 0.22% 0.01 0.98% 0.27 0.12% 0.23 1.93% 0.967
55 0.22% 0.01 0.93% 0.25 0.11% 0.22 1.76% 0.970
60 0.22% 0.01 0.89% 0.24 0.11% 0.22 1.62% 0.972
65 0.22% 0.01 0.85% 0.23 0.11% 0.21 1.50% 0.974
70 0.22% 0.01 0.82% 0.22 0.10% 0.20 1.39% 0.976
75 0.22% 0.01 0.79% 0.22 0.10% 0.20 1.30% 0.978
80 0.22% 0.01 0.77% 0.21 0.10% 0.19 1.22% 0.979
85 0.22% 0.01 0.75% 0.20 0.10% 0.19 1.15% 0.980
90 0.22% 0.01 0.72% 0.20 0.09% 0.19 1.09% 0.981
95 0.22% 0.01 0.70% 0.19 0.09% 0.18 1.04% 0.982
100 0.22% 0.01 0.69% 0.19 0.09% 0.18 0.99% 0.983
105 0.22% 0.01 0.67% 0.18 0.09% 0.18 0.94% 0.984
110 0.22% 0.01 0.65% 0.18 0.09% 0.17 0.90% 0.985
115 0.22% 0.01 0.64% 0.17 0.08% 0.17 0.86% 0.985
120 0.22% 0.01 0.63% 0.17 0.08% 0.17 0.83% 0.986
125 0.22% 0.01 0.61% 0.17 0.08% 0.16 0.79% 0.986
130 0.22% 0.01 0.60% 0.16 0.08% 0.16 0.76% 0.987
135 0.22% 0.01 0.59% 0.16 0.08% 0.16 0.74% 0.987
140 0.22% 0.01 0.58% 0.16 0.08% 0.16 0.71% 0.988
145 0.22% 0.01 0.57% 0.15 0.08% 0.16 0.69% 0.988
150 0.22% 0.01 0.56% 0.15 0.08% 0.15 0.66% 0.989
155 0.22% 0.01 0.55% 0.15 0.08% 0.15 0.64% 0.989
160 0.22% 0.01 0.54% 0.15 0.07% 0.15 0.62% 0.989
165 0.22% 0.01 0.53% 0.14 0.07% 0.15 0.61% 0.990
170 0.22% 0.01 0.52% 0.14 0.07% 0.15 0.59% 0.990
175 0.22% 0.01 0.52% 0.14 0.07% 0.14 0.57% 0.990
180 0.22% 0.01 0.51% 0.14 0.07% 0.14 0.56% 0.990
gFOBT 0.22% 0.01 0.4% 0.11 0.11% 0.21 1.01% 0.983
The definition of False positives includes positives with no LR/HR adenomas or CRC
LR adenoma detection rate assumed same as for gFOBT as no data available from FIT pilot.
HR adenomas are those which receive surveillance within the BCSP (classified as intermediate or high risk).
LR adenoma detection rate 0.2% (0.2%,0.2%)
LR adenoma sensitivity 0.6% (0.5%,0.6%)
HR adenomas detection rate 0.4% (0.3%,0.4%)
HR adenoma sensitivity 9.7% (9.3%,10.2%)
CRC detection rate 0.1% (0.1%,0.1%)
CRC sensitivity 16.8% (15.1%,18.5%)
False positives 0.7% (0.6%,0.7%)
1-specificity 1.1% (1.1%,1.2%)
BCSP gFOBT: round 1, age 60
We note that specificity calculations relate to persons without LR/HR 
adenomas or CRC.
Persons without adenomas of CRC may have other conditions which may 
explain why 1-specificity is higher the and LR adenomas sensitivity.
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sensitivity to cancer compared to values reported by Murphy & Gray (2015) [4] which ranged from 57.5% for 
FIT 20 µg/ml to 29.5% for FIT 180 µg/ml.  
BCSP Bowel Scope 
For the bowel scope analysis, data from the NHS BCSP was used. This data includes approximately 240,000 
bowel scope procedures undertaken in persons aged 55. The detection rates for age 60 were estimated from 
this data using the relative detection rates observed in the UKFSST for which we have age categorised data for 
persons of ages 55-65. For bowel scope screening LR adenomas may be identified at BS or at referral 
colonoscopy. The NHS BCSP data only contains information about those persons detected with LR adenomas 
at colonoscopy hence the more detailed UKFSST data was used to supplement this. In both the UKFSST data 
and the BCSP data the detection rate for LR adenomas at colonoscopy was just over 1% however, the UKFSST 
data suggests a significant number of LR adenomas (approximately 8%) are also detected at BS (in persons not 
referred on to colonoscopy). We note that the test characteristics for bowel scope relate to the entire 
ƐĐƌĞĞŶŝŶŐĞƉŝƐŽĚĞŝ ?Ğ ? ‘ďŽǁĞůƐĐŽƉĞƉůƵƐŝŶĚĞǆĐŽůŽŶŽƐĐŽƉǇĨŽƌƚŚŽƐĞǁŚŽĂƌĞƌĞĨĞƌƌĞĚĂŶĚĂƚƚĞŶĚ ? ? 
 
The UKFSST is also included here for comparative purposes. For the model base case the BCSP BS data was 
used as it includes a higher number of bowel scope procedures and is more likely to reflect how the bowel 
scope screening programme performs in practice. Improvements in bowel scope quality could result in higher 
HR adenoma and CRC sensitivity as observed in the UKFSST and this was explored within a scenario analysis. 
 
For persons aged 60 we know approximately that: (1) 69% of CRC incidence is distal; (2) 70% of persons with 
adenomas have some distal adenomas; (3) 10% of the CRC detected within the UKFSST was proximal. If BS 
detected 95-98% of distal CRC (colonoscopy sensitivity) then BS may be expected to detect 72-74% of all CRC 
(68% distal + 6% proximal). Hence we hypothesise that 72-74% is an upper bound on BS sensitivity to CRC. This 
is just slightly higher than the sensitivity estimate from the UKFSST. 
 
Table 12: Bowel Scope screening test characteristics estimates 
 
 
Other data sources 
Literature reviews were undertaken to identify other data sources for test characteristics. Rapid searches were 
undertaken around key words for for FIT or gFOBT together with filters for colon cancer, diagnostics and 
reviews. In total, 19 reviews were found for FIT and 77 for gFOBT. Most of these were not relevant, however 
several systematic reviews were identified which examined the sensitivity and specificity of screening tests, 
from clinical trials comparing each test against the standard of colonoscopy. FIT20 screening was estimated to 
have an average sensitivity for CRC of about 78%, which is much higher than that estimated from the FIT pilot, 
and an average sensitivity for advanced adenomas ranging between 22% and 34%. Note that advanced 
adenomas make up only a subset of high risk adenomas so it is unsurprising that this figure is lower than that 
estimated from the FIT pilot for high risk adenomas. Less data was found to inform gFOBT test characteristics, 
with only one small, fairly representative trial finding sensitivity to CRC of 31% and sensitivity to advanced 
adenomas of 14%, both of which are considerably higher than was estimated from BCSP data. The review 
indicates that in general, trials give higher estimates of screening sensitivity compared to estimates derived 
BCSP Bowel Scope UKFSST
Age 60 (estimated using 
UKFSST data)
LR adenomas detection rate 9.0% (8.6%,9.4%) 9.0% (8.6%,9.4%)
LR adenomas sensitivity 24.1% (23.0%,25.1%) 24.1% (23.0%,25.1%)
HR adenomas detection rate 2.5% (2.4%,2.5%) 2.9% (2.6%,3.1%)
HR adenomas sensitivity 67.7% (66.0%,69.4%) 78.1% (71.9%,84.4%)
CRC detection rate 0.2% (0.2%,0.2%) 0.3% (0.3%,0.4%)
CRC sensitivity 43.7% (40.0%,47.5%) 67.9% (52.0%,83.8%)
False positives rate NA NA
Specificity assumed 100% assumed 100%
Age 60, first screen
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from screening pilots or programmes. This is unsurprising as trial populations are likely to be unrepresentative 
of the general population.   
 
Summary 
Table 13 summarises the screening test characteristics estimates used within the model for FIT, BS and 
gFOBT. 
Table 13: Summary of screening test characteristic estimates 
 
 
Colonoscopy characteristics 
Colonoscopy characteristics were estimated using a systematic review of studies of tandem colonoscopies was 
undertaken by Van Rijn et al [48]. For adenomas of size <10mm, 167 out of 711 were missed, and for 
adenomas of size >10mm, 2 out of 96 were missed. A study by Bressler et al estimated that out of 12,496 cases 
of CRC, 430 were missed at colonoscopy (2%) [49]. Based on these studies, sensitivity to low risk adenomas 
was assumed to be 77%, sensitivity to high risk adenomas or CRC 98%, and specificity was assumed to be 
100%.  
CTC characteristics 
Data on difference in detection rates for gFOBT positives receiving CTC compared to colonoscopy is available 
however this cannot be used to derive CTC test characteristics as the screen positive cohort who are offered 
CTC are older and more frail.  
The SIGGAR1 study comprised two multicentre, randomised trials comparing CTC with barium enema (BE) and 
colonoscopy in patients with symptoms suggestive of CRC [50, 51]. The main objective was to establish how 
CTC compares with BE and colonoscopy for the investigation of patients with symptoms of CRC. Data from the 
SIGGAR1 trial was used to define CTC characteristics in the model. Published data from the trial indicates that 
the relative risk of CRC detection with CTC compared to colonoscopy is 0.98, the relative risk of detection of a 
ƉŽůǇƉA䠀  ? ?ŵŵŝs 0.82, and the combined relative risk (caŶĐĞƌŽƌƉŽůǇƉA䠀  ? ?ŵŵ ?ŝƐ ? ? ? ?[50]. In the absence of 
further data it was assumed that the relative risk of detection of low risk adenomas was the same as that of 
high risk adenomas (0.82). These relative risks were combined with the colonoscopy sensitivities described 
above to provide estimates of CTC sensitivity (48% for low risk adenomas, 80% for high risk adenomas, 96% for 
CRC and 87% for combined cancer or high risk adenoma). 
A systematic review of the effectiveness, diagnostic accuracy and harms of CRC screening was recently carried 
out to inform the US Preventive Services Task Force [52]. The review included seven studies, none from the 
UK, which estimated the sensitivity and specificity of CTC screening. The weighted mean sensitivity was 
calculaƚĞĚĂƐ ? ?A?ĨŽƌĂĚĞŶŽŵĂƐA? ?ŵŵ ?Žƌ ? ?A?ĨŽƌĂĚĞŶŽŵĂƐA? ? ?ŵŵ ǁŚĞƌĞĂƐƚŚĞǁĞŝŐŚƚĞĚŵĞĂŶ
FIT pilot BCSP Bowel Scope UKFSST BCSP gFOBT
threshold 120 mg Hb/g 
faeces
Age 60, first screen Age 60, first screen Age 60, first screen
LR adenomas detection rate 0.2% (0.1%,0.4%) 9.0% (8.6%,9.4%) 9.0% (8.6%,9.4%) 0.2% (0.2%,0.2%)
LR adenomas sensitivity 0.6% (0.3%,1.0%) 24.1% (23.0%,25.1%) 24.1% (23.0%,25.1%) 0.6% (0.5%,0.6%)
HR adenomas detection rate 0.6% (0.4%,0.9%) 2.5% (2.4%,2.5%) 2.9% (2.6%,3.1%) 0.4% (0.3%,0.4%)
HR adenomas sensitivity 17% (11%,24%) 67.7% (66.0%,69.4%) 78.1% (71.9%,84.4%) 9.7% (9.3%,10.2%)
CRC detection rate 0.1% (0.0%,0.2%) 0.2% (0.2%,0.2%) 0.3% (0.3%,0.4%) 0.1% (0.1%,0.1%)
CRC sensitivity 17% (4%,39%) 43.7% (40.0%,47.5%) 67.9% (52.0%,83.8%) 16.8% (15.1%,18.5%)
False positives rate 0.8% (0.6%,1.1%) NA NA 0.7% (0.6%,0.7%)
1-Specificity 1.4% (1.0%,1.9%) assumed 100% specific assumed 100% specific 1.1% (1.1%,1.2%)
Age 60 (estimated using 
UKFSST data)
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ƐƉĞĐŝĨŝĐŝƚǇǁĂƐĐĂůĐƵůĂƚĞĚĂƐ ? ?A?ĨŽƌĂĚĞŶŽŵĂƐA䠀  ?ŵŵ ?Žƌ  ?A?ĨŽƌĂĚĞŶŽŵĂƐA䠀  ? ?ŵŵ ?dƐƉĞĐŝĨŝĐŝƚǇŝŶƚhe 
model was assumed to be 88%. 
Table 14: Diagnostic test characteristics 
Characteristic Value Source 
Colonoscopy Sensitivity (low risk adenomas) 77% Van Rijn et al 2006 [48] 
Colonoscopy Sensitivity (high risk adenomas) 98% Van Rijn et al 2006 [48] 
Colonoscopy Sensitivity (colorectal cancer) 98% Bresler et al 2007 [49] 
Colonoscopy Specificity  100% Assumption 
CTC Sensitivity (low risk adenomas) 48% Based on relative risk from Atkin et al 
2013 [50] 
CTC Sensitivity (high risk adenomas) 80% Based on relative risk from Atkin et al 
2013 [50] 
CTC Sensitivity (colorectal cancer) 96% Based on relative risk from Atkin et al 
2013 [50] 
CTC Specificity  88% Lin et al 2016 [52] 
 
Test completion rates 
The bowel cancer screening pilot 2nd round evaluation reported that 5% of initial FOBTs had 1-4 positive spots 
(weak positive) so require repeat testing per the NHS BCSP referral algorithm [53]. The study also reported 
that 0.4% of returned kits were inadequate. 66,264 gFOBTs were completed in phase 1, 2,972 in phase 2 and 
2,236 in phase 3 hence the mean number of tests completed per person was 1.08. 
Repeat testing will be required for FIT kits which are not returned within a certain period. The period of time in 
which a test must be returned is unclear, but we assume that a test must be returned within 7-10 days. 
Approximately 97% of gFOBTs are returned within 7 days and 95% within 5 days, hence the retest rate for FIT 
was assumed to be 3%. The Italian screening programme reported that 0.6% of persons had an inadequate 
test (due to incorrect sampling by the subject) [19]. 
The bowel scope screening trial reported that out of 40621 examinations undertaken, 2145 (5%) required 
repeating, and out of these 1306 (3%) were repeated on the same day and 839 (2%) were repeated on a later 
day [54].  It was assumed that BS examinations repeated on the same day incurred no additional costs and that 
if the examination was repeated on a later day then the cost of an additional BS examination would be 
incurred. 
Out of a total of 32,213 screening referral colonoscopies undertaken from Aug 2006 to Aug 2008 in the NHS 
BCSP, in 1,481 (4.6%) the caecum was not reached, which could be due to pathology encountered, inadequate 
bowel preparation or patient discomfort. One can assume that majority of the 1,481 will have required a 
subsequent test which would usually be undertaken on a later day (personal communication from Tom Lee, 
ERFUHoNT). Persons requiring a subsequent test will receive a colonoscopy, a CT colonography or a barium 
enema. Data from the NHS BCSP reports that out of 78,311 colonoscopy examinations, 5,453 people (7%) who 
return within an episode to have another procedure, which could be to remove more adenomas, to complete 
an incomplete test, or to check an adenoma removal site [1]. Hence a repeat colonoscopy rate of 7% is 
assumed here.  
A study of BCSP data collected between 2006 and 2012 reports that of 1027 suspected polyp or cancer cases 
detected using CTC, 911 (88.7%) were referred for further investigation before diagnosis could be reached 
[26]. Further investigation may comprise colonoscopy, or if the patient is unsuitable for colonoscopy (perhaps 
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due to obstruction of the bowel), then surgery may be performed. A repeat investigation rate of 89% was 
applied to CTC in the model. It was assumed that all repeat investigations used colonoscopy. 
Table 15: Test completion 
Test Mean Number Tests Completed Source 
gFOBT 1.08 Weller et al 2007 [53] 
FIT 1.01 Zorzi et al 2009 [19] 
 Proportion Incomplete/Repeated  
Bowel scope 2.1% Atkin et al 2002 [54] 
Colonoscopy  7.0% BCSP [1] 
CTC  88.7% Plumb et al 2013 [26] 
5.3.3 Screening attendance and compliance with follow-up and surveillance 
Uptake of gFOBT  
Uptake is defined as the proportion of individuals invited for screening who give an adequate sample. A small 
proportion of people opt out from screening for clinical reasons or informed dissent after receiving an 
invitation, and do not receive a test kit. These individuals are not invited for further screening rounds unless 
they later opt back in. The number of individuals opting out is not recorded by the BCSP. The majority of 
individuals who fail to take up screening are sent a test kit but do not return it. The overall uptake rate for 
financial year 2014/15 is 58.24% according to the BCSP [1]. This includes both prevalent (first time 
participation) and incident (subsequent invites following a first participation) screening rounds.  
When modelling just one round of screening, varying the uptake rate has little effect on cost-effectiveness. 
This is because costs for non-attenders are very low, so an increase in uptake would lead to a proportional 
increase in both costs incurred and QALYs gained. In reality, however, the situation is more complex. For 
example, if we consider two scenarios both associated with 50% uptake: all persons attend 50% of screening 
rounds; and 50% of persons attend all screening rounds; we see that it is likely that these two scenarios will be 
associated with differing QALY gains. 
The modelling approach taken here partitions the population into subgroups according to their preference for 
ƐĐƌĞĞŶŝŶŐ P “ƐŽŵĞƚŝŵĞƐĂƚƚĞŶĚ ?ĂŶĚ “ŶĞǀĞƌĂƚƚĞŶĚ ? ?dŽĚĂƚĞ ?^WĚĂƚĂŝŶĐůƵĚĞƐƚŚĞĞŶƚŝƌĞĨŝƌƐƚĨŽƵƌƌŽƵŶĚƐŽĨ
screening [1], which is insufficient to accurately define the proportion ŽĨ “ŶĞǀĞƌĂƚƚĞŶĚĞƌƐ ?, given that an 
individual is likely to be eligible for up to eight screening rounds between the ages of 60 and 74. Within the 
four rounds of screening performed so far, 66% of invited individuals have been screened at least once and 
34% never screened. With each subsequent round of invitations, a diminishing proportion of individuals who 
have never been previously screened complete an adequate screening test (Table 16). 
Table 16: Prevalent gFOBT screening uptake and proportion of individuals never screened in subsequent 
screening rounds (BCSP 2014/15 [1]) 
Screening Episode Prevalent Uptake Proportion Never 
Screened 
Proportion Screened at 
least Once 
Round 1 49% 51% 49% 
Round 2 18% 41% 59% 
Round 3 11% 37% 63% 
Round 4 8% 34% 66% 
 
The proportion of persons who sometimes attend and the attendance rate for this group was chosen so that 
the number of persons attending one or more of the first four rounds matches that seen in the current gFOBT 
screening programme. If someone has previously taken up a screening invitation, then the probability that 
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they will take up subsequent invitations is much higher than if they have not previously taken up a screening 
invite. Over the past four screening rounds, the figure for incident screening uptake i.e. the attendance rate for 
 “ƐŽŵĞƚŝŵĞƐĂƚƚĞŶĚĞƌƐ ?ŝƐ ? ? ? ? ?A? ?dŚĞƉƌŽƉŽƌƚŝŽŶŽĨƉĞƌƐ ŶƐǁŚŽƐŽŵĞƚŝŵĞƐĂƚƚĞŶĚŝƐĞƐƚŝŵĂƚĞĚĂƐƚŚĞŵĞĂŶ
overall uptake rate divided by the mean incident uptake rate (0.85/0.58 = 68%). As expected, this is slightly 
higher than the proportion screened at least once following four rounds of screening shown in Table 16. 
Table 17: Participation rates for screening 
Test Parameter Value Source 
gFOBT Mean overall uptake rate 58% BCSP 2014/15 [1] 
Mean incident uptake rate 85% BCSP 2014/15 [1] 
Proportion screened at least once over 
all rounds 
68% Estimated from above values 
FIT Mean overall uptake rate 65% RR compared with gFOBT from 
Moss et al 2016 [2] 
Mean incident uptake rate 90% RR compared with gFOBT from 
Moss et al 2016 [2] 
Proportion sometimes attenders 73% Estimated from above values 
FS Screening compliance 44% BCSP 2014/15 [1] 
Colonoscopy Compliance following FOBT 87% BCSP 2014/15 [1] 
Compliance following FS 96% Atkin et al 2002 [54] 
Surveillance compliance 82% BCSP [1] 
 
Uptake varies by gender and age (see section 3.1) but the modelling approach does not currently allow this to 
be incorporated. This simplification could be considered a limitation of the modelling approach. Further 
analysis of uptake data would allow a more sophisticated model of uptake to be considered in the future.  
Uptake of FIT 
Data for uptake of FIT was obtained from the recent UK FIT pilot study [2]. The study compared gFOBT and FIT 
screening and found that uptake of FIT is consistently higher than uptake of gFOBT, likely due to the ease of 
use of the FIT test kit. This result is particularly marked in groups that are less responsive to screening but at 
higher risk of CRC, including men and those who are socioeconomically deprived. Uptake values for gFOBT 
reported in the study differ slightly from those described above due to the model using more recent BCSP 
data. To standardise the FIT data from the pilot study to the current BCSP data, relative risks for total uptake 
compared with gFOBT and incident screening rate compared with gFOBT were calculated and multiplied with 
the BCSP gFOBT data to derive a total uptake of 65% and an incident screening rate of 90% for use in the 
model (see calculation example for total uptake in Table 18). As with gFOBT, an estimate of the proportion of 
 “ƐŽŵĞƚŝŵĞƐĂƚƚĞŶĚĞƌƐ ?ŚĂƐďĞĞŶĐĂůĐƵůĂƚĞĚĂƚ ?3% (Table 17).  
Table 18: Example of FIT total uptake calculation using FIT pilot [2] and BCSP data [1] 
a: gFOBT total uptake in FIT pilot 0.59 
b: FIT total uptake in FIT pilot 0.66 
c: Relative Risk for uptake of FIT compared with gFOBT in FIT pilot (=b/a) 1.12 
d: Total uptake gFOBT in BCSP 0.58 
e: Estimate of FIT total uptake (=c*d) 0.65 
 
Uptake of bowel scope 
Data on uptake of BS was obtained from the BCSP for the financial year 2014/15 [1]. In total 77,149 individuals 
were invited for BS screening, of which 40,974 responded but only 34,265 attended, resulting in an uptake rate 
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of 44.41%. Given that BS is a one-off screen at age 55 that has been introduced fairly recently, it was not 
relevant to model incident or prevalent uptake.  
Compliance with follow-up and surveillance colonoscopy 
Data from the NHS BCSP reports compliance rates of 87.2% for screening referral colonoscopy or CTC following 
gFOBT [1]. It was assumed that this would be the same for FIT. Data for follow-up compliance following BS 
screening was not available from the BCSP and instead was taken from the BS screening trial [54]. This is 
higher than compliance following FOBT screening at 96.3%, likely due to these individuals already having 
consented to and undergone a fairly invasive screening procedure. Compliance was assumed to be 82.4% for 
persons invited for surveillance colonoscopy, in line with data from the BCSP [1]. Compliance for follow-up CTC 
was assumed to be 99% in line with estimates presented in a study of data from the BCSP. 
Complications following endoscopy/CTC 
Colonoscopy, bowel scope and CTC procedures are associated with a small risk of bleeding or perforation; and 
perforation may lead to death. Incidence of hospitalisation for bleeding and perforation following flexible 
sigmoidoscopy with or without polypectomy are taken from the flexible sigmoidoscopy trial [54]. This trial also 
reported the rate of perforation for colonoscopy, which were used in previous versions of the model. However 
these values have been updated in the current version of the model using data from a more recent study of 
130,831 patients undergoing colonoscopy in the BCSP [55]. This reports a colonoscopy perforation rate of 
0.031% without polypectomy, and 0.091% with polypectomy, with an average of 2.3 polypectomies per 
patient. The rate of bleeding requiring transfusion (represented in the model as hospitalisation) was 0.04%. 
Gatto et al report that the incidence of death subsequent to a perforation within 14 days of a procedure was 4 
out of 77 colonoscopic perforations (5.2%) and 2 out of 31 sigmoidoscopic perforations (6.5%) [56]. This study 
refers to a Medicare population, so the cases may be older and in worse health than the proposed English 
screening population; however, no alternative reference was identified. Gatto et al also reported that the risk 
of perforation from BS increased in association with increasing age, but this association has not been modelled 
here [56]. 
Risk of perforation following CTC is even lower than for colonoscopy. A rate of 0.02% is assumed, in line with 
results from a systematic review and meta-analysis of the data [57]. No individuals died following perforation 
in any of the included studies, so mortality rate following CTC is assumed to be 0%. 
Risks of CTC are fairly low and tend to occur in patients with contributing conditions such as inflammatory 
bowel disease [58]. There is a small risk of bowel perforation, estimated in a recent meta-analysis of 100,000 
individuals to be only 0.02% in screening subjects (0.04% if all patients are considered) [57]. Only 0.008% of 
patients will require surgery due to the CTC process and no deaths were recorded [57]. This is considerably 
lower than the risk of perforation from colonography. Lifetime risk of radiation-related cancer due to a single 
CTC scan has been estimated at around 0.05% at age 60, doubled if a chest or abdominal/pelvic scan is also 
performed. Risk varies by age, being higher in younger people due to their longer lifespan. 
Table 19: Complications following Endoscopy/CTC 
Complication Cost  Source 
Colonoscopy (without Biopsy) Perforation Rate 0.031% BCSP (Rutter 2014 [55]) 
Colonoscopy (with Biopsy) Perforation Rate 0.091% BCSP (Rutter 2014 [55]) 
Colonoscopy Probability of Death following 
Perforation 
5.2%  Gatto et al 2003 [56] 
Colonoscopy Probability of Hospitalisation for 
Bleeding 
0.04% BCSP (Rutter 2014 [55]) 
BS (without Biopsy) Perforation Rate 0.0% BS UK Screening Trial, 2002 [54] 
BS (with Biopsy) Perforation Rate 0.0% BS UK Screening Trial, 2002 [54] 
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BS Probability of Death following Perforation 6.5% Gatto et al 2003 [56] 
BS Probability of Hospitalisation for Bleeding 0.03% BS UK Screening Trial, 2002 [54] 
CTC Perforation Rate 0.02% Bellini et al 2014 [57] 
CTC Probability of Death following Perforation 0.0% Bellini et al 2014 [57] 
 
5.3.4 Utility values 
A utility value is a preference weight reflecting the relative value that individuals place on different health 
states. Here different utility values are used for persons with CRC and for persons without CRC. NICE 
recommends that utilities should be based upon public preferences (e.g. EQ-5D values) and valued by patients 
[27]. Given that the focus of the model is comparison of screening strategies at different ages, and that 
screening may result in earlier detection of CRC (which may also be at an earlier stage) it is also particularly 
important that age and stage dependent utilities are included in the model. As one of the screening strategies 
considered is that of not screening, it is also important that a comparison with the health-related quality of life 
of the general population is considered. 
For this study, de novo utility estimates werĞŐĞŶĞƌĂƚĞĚ ?ďĂƐĞĚŽŶĂƐƵďũĞĐƚ ?Ɛ age, whether or not they have 
CRC, and for those with CRC, whether or not it was at an advanced stage (stage D). The sub-division of CRC into 
advanced and non-advanced cancers is used as there is a paucity of evidence to derive more refined stage-
specific values for CRC. The utility values used for this study are presented in Table 20. 
Table 20: Utilities used in the model for the basecase scenario 
Age Group Without CRC With CRC  ? stage A-C With CRC  ? stage D 
30-34 0.9111 0.8679 0.6692 
35-39 0.8974 0.8533 0.6579 
40-44 0.8835 0.8384 0.6465 
45-49 0.8675 0.8216 0.6335 
50-54 0.8508 0.8045 0.6204 
55-59 0.8326 0.7855 0.6057 
60-64 0.8130 0.7653 0.5901 
65-69 0.7919 0.7436 0.5734 
70-74 0.7696 0.7199 0.5551 
75-79 0.7441 0.6943 0.5354 
80-84 0.7193 0.6669 0.5142 
85+ 0.6846 0.6295 0.4854 
 
The evidence sources used to derive these utility values were: 
x Pooled data from the Health Survey for England for the years 2003 to 2014 inclusive (excluding years 
2007, 2009 and 2013 as no data were collected for these) [59]. This provided age-specific data on 
health-related quality of life for people with and without cancer, measured using the EQ-5D-3L. It was 
assumed that the utility values observed for people with cancer would be applicable to people with 
CRC.  
x Results from a systematic review and meta-analysis for CRC studies [60], which enabled results for 
CRC patients to be broken down into advanced (stage D) and non-advanced (stage A-C) stages. 
Full details of the analysis methods undertaken are provided in Appendix D. 
There may be a small utility decrement associated with undergoing a screening test; however, such a 
decrement is likely to only last a short period of time. There is no data available for utility values during a 
screening test, so no utility decrement due to screening test was included within the modelling.  
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Disutility values were sought for patients who experience adverse events during polypectomy such as bowel 
perforation or bleeding. However, we were not able to identify values for disutilities for these events from the 
literature. As an alternative we estimated values for disutility for bleeding by assuming they would be similar 
to a major gastrointestinal bleed and used the value from Dorian and colleagues of 0.1511 for two weeks, i.e. a 
total QALY loss of 0.006 [61]. Values for perforation were assumed to be the same as for stomach 
ulcer/abdominal hernia/rupture taken from Ara and Brazier [62]. The disutility value was 0.118 for one month, 
i.e. total QALY loss of 0.010. 
 
5.4 Modelling subgroup risk of CRC incidence and mortality 
A subgroup with a higher risk of CRC than the general population (e.g. males) will have a different cancer 
disease natural history to the general population. The exact way in which the disease natural history model will 
vary between subgroups with different CRC risk is not known. For example, whether difference is in the rate at 
which precancerous conditions develop, the rate at which precancerous conditions transition to cancer, or 
both of these.  
Data from the NHS BCSP 2014/2015 shows that compared to the general population males have a higher 
proportion of both adenomas and CRC detected suggesting a higher rate of adenoma development.  
In the absence of other data we make the assumption here that for subgroups with higher CRC incidence the 
rate of adenoma development is higher but the rate of progression from adenomas to CRC remains 
unchanged. This was implemented by adjusting the rate of transition from normal epithelium to LR (by the 
same multiplier for all ages) so that the expected incidence changes. Firstly the model was run applying a 
ƌĂŶŐĞŽĨĚŝĨĨĞƌĞŶƚƌĞůĂƚŝǀĞƌŝƐŬƚŽƚŚĞ ‘EŽƌŵĂů-ANůŽǁƌŝƐŬĂĚĞŶŽŵĂƐ ?ƚƌĂŶƐŝƚŝŽŶƉƌŽďĂďŝůŝƚŝĞƐĂŶĚƚŚĞƌĞůĂƚŝǀĞ
change in incidence was recorded in each case. These value were then stored in a table so that the appropriate 
transition probabilities multiplier could be looked up for the required incidence relative risk. 
If the incidence and mortality relative risks were similar this would imply that differences in mortality were as 
a direct result of differences in incidence (assuming a similar stage distribution of incidence). The mortality 
relative risks for deprivation are greater than the incidence relative risks so in addition to having higher 
incidence these subgroups are also associated with poorer survival. The ratio of incidence and mortality 
relative risks was applied to the mortality rates in the model. 
 
5.5 Repeated and combination screening strategies 
A key benefit of economic modelling over and above trial data is the ability to simulate the results for a 
number of screening strategies for which there are no trial evidence. Several analyses were undertaken to 
determine what repeated screening strategies are optimal. Analyses were undertaken comparing screening 
strategies which had the same endoscopy capacity. 
For repeated FIT screening strategies the maximum age range we considered was 50-74 years.  We restricted 
the screening strategies considered to those which used the same FIT threshold across all screening ages and 
those which had a constant screening interval. Strategies which relax these two constraints will be considered 
as part of phase 2. Screening strategies considered included those with: starting ages between 50 and 60; 
screening intervals of 1, 2, 3, 4, 5 or 6 years;  3 or more screens; any FIT threshold between 20 and 180. 
Strategies which included a one-off bowel scope screen and repeated FIT screening were also considered. 
 
43 
 
5.6 Model validation 
The model was validated in several different ways to check different aspects of the model against other CRC 
models, trial data and population data to help identify errors and explain any differences. Full details of model 
validation can be found in Appendix E, but a summary of validations performed and results obtained is given 
here.  
Recent CRC incidence statistics 
Model predictions of CRC incidence and mortality were compared against the most recent CRC incidence 
statistics [7] and ONS death certificate data [34] from 2014. These validations indicated that the model 
predicts recent CRC incidence fairly accurately. CRC mortality from death certificate data is slightly over-
estimated by simulating a no screening scenario and slightly under-estimated by simulating steady state gFOBT 
roll-out, thereby fairly accurately representing the 2014 status of screening had been taking place for 
approximately 6 years (BCSP was introduced in 2006-2009). 
Previous economic analysis including FIT 
Model results were validated against those obtained in the FIT versus gFOBT cost-effectiveness analysis 
performed by Jacqueline Murphy and Alastair Gray in order to check for inconsistencies between the two 
models and determine the effect of updating parameters [4]. Whilst the two models are broadly similar, 
ScHARR model updates have a significant impact on cost-effectiveness results such that comparison of FIT with 
gFOBT testing in the ScHARR model is highly cost-effective but not cost-saving as found in the Murphy & Gray 
analysis. This difference arises predominantly due to updates in CRC treatment costs, which are much lower in 
the ScHARR model, meaning that the reduction in cancer cases seen with FIT screening compared to gFOBT 
screening saves insufficient incremental costs to outweigh the additional costs of screening. The ScHARR 
model uses updated data for CRC survival which results in lower expected incremental life years and QALYs. 
Long term follow up screening trial data 
CRC incidence and mortality results were compared with the 20 year follow-up of the Nottingham randomised 
controlled trial of gFOBT screening vs no screening to check how closely the model reproduces long-term 
results [3]. The validation suggests that the model accurately estimates CRC mortality reduction due to 
screening, but is slightly overestimating gFOBT effectiveness in reduction of cancer incidence, although model 
findings are within the trial 95% confidence intervals. Mortality estimates were highly dependent upon the 
year from which mortality data and life tables were taken, indicating the importance of adjusting mortality 
parameters to reflect the study setting when performing validations. 
Secondly, FS model results were validated against the FS trial 11 year and 17 year follow-up data [5]. Model 
predictions of CRC incidence reductions due to screening were very close to FS data, whilst CRC mortality was 
slightly over-estimated by the model and the benefits of screening on mortality were underestimated (albeit 
within 95% confidence intervals). Once again, mortality estimates were highly dependent upon the mortality 
parameters used. We note that the ScHARR model performed well in validation when compared to the recent 
validation of the CISNET model to the FS trial data.[6] 
Surveillance 
Data from the BCSP on number of surveillance colonoscopies carried out was compared with estimates of 
surveillance colonoscopy usage in the model. The model overestimates surveillance colonoscopy by around 
two-fold which is a significant discrepancy. The data informing the surveillance model parameters are 
associated with significant uncertainty. The uncertain ƉĂƌĂŵĞƚĞƌƐŝŶĐůƵĚĞ ‘ĂĚĞŶŽŵĂƌĞĐƵƌƌĞŶĐĞƌĂƚĞĨŽůůŽǁŝŶŐ
ƉŽůǇƉĞĐƚŽŵǇ ? and  ‘ƉƌŽƉŽƌƚŝŽŶŽĨĂĚĞŶŽŵĂƐƌĞĨĞƌƌĞĚĨŽƌĂŶŶƵĂů ? ?-ǇĞĂƌůǇƐƵƌǀĞŝůůĂŶĐĞ ? ?dŚĞŝŵƉĂĐƚŽĨƚŚĞƐĞ
uncertainties was explored by varying these parameter values however this uncertainty could not entirely 
explain differences between model predictions and BCSP data. Further validation is required to explore these 
differences however data from the BCSP to enable this was not available within the timescale of this project. 
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This issue will be examined as part of more detailed surveillance modelling in Phase 2. As a result of the 
differences between the ScHARR model predictions and BCSP data the model predicted surveillance 
colonoscopy estimates presented here should be treated with caution. 
 
5.7 Sensitivity analyses 
A series of sensitivity analyses were undertaken to explore the impact of specific uncertainties (both 
parameter values and modelling assumptions) on model results. For each sensitivity analysis, only the range of 
screening options defined in the final results tables were analysed. 
Discount rate 
A scenario analysis in which discount rates for costs and utilities were both set to 1.5% was undertaken. 
Costs 
A sensitivity analysis around CRC treatment costs was undertaken in which lower treatment costs were applied 
(obtained from the INCISIVE report). A sensitivity analysis around the cost of bowel scope was undertaken with 
cost of £150 and £450. 
Screening uptake 
Sensitivity analyses were undertaken which explored different screening uptake rates. An analysis in which the 
uptake of FIT was assumed to be the same as the current gFOBT uptake was undertaken. Expert opinion 
suggested that it is likely that bowel scope uptake will increase over time due to normalisation of the 
procedure (Personal communication from Wendy Atkin). Current bowel scope uptake is 44%; an analysis with 
higher bowel scope uptake (55%) was undertaken. 
Screening test characteristics 
For the model base case the BCSP BS data was used as it includes a higher number of bowel scope procedures 
and is more likely to reflect how the bowel scope screening programme performs in practice. Improvements in 
bowel scope quality could result in higher HR adenoma and CRC sensitivity as observed in the UKFSST and this 
was explored within a scenario analysis. In this scenario analysis bowel scope test sensitivity was higher 
based on data from UKFSST, and a higher uptake of 55% was also applied. 
 
The base case assumes that screening tests will be independent when used in combination (e.g. FS followed by 
FIT) or as a repeated test (e.g. biennial FIT). However, it is possible that sensitivity and specificity are reduced 
in subsequent tests [18]. As the structure of the model makes it difficult to assign different characteristics to 
repeat tests, a sensitivity analysis was carried out where it was assumed that sensitivity of FIT and gFOBT was 
25% lower. A second sensitivity analysis was carried out where in addition to the reduced sensitivity, specificity 
was also reduced in line with the findings from Kearns et al (2014) [18].  
Colorectal cancer natural history model 
Symptomatic presentation rates may be changing over time with increased symptom awareness. The model 
currently uses presentation rates based on pre-screening data (as this data is not confounded by screening). To 
explore this uncertainty, scenario analyses in which the rates of symptomatic presentation were increased by 
5% or by 10% from baseline estimates was undertaken. 
Population subgroups 
It is known that screening uptake and cancer incidence vary for certain population subgroups. Screening 
strategies which vary by population characteristics will be explored in Phase 2 of this work programme. An 
exploratory scenario analysis which considered either an entirely male or entirely female population was 
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undertaken here to demonstrate the importance of such subgroup differences. Male/female screening uptake 
rates and colorectal cancer risk were applied for these analyses.   
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6 Results 
6.1 Optimising Cost-effectiveness 
The following analyses focus on maximising cost effectiveness which we measure as Net Monetary 
Benefit (NMB) which is defined as: 
incremental QALYs* WTP threshold ʹ incremental costs 
We set the WTP threshold to £20,000 per QALY. Results presented are the discounted lifetime total 
costs (screening, treatment and surveillance costs) and QALYs for the population of England. 
It is essential for the reader to understand that the optimal screening strategy will vary depending 
on what outcome measure you consider. For example, the optimal screening strategy will vary 
depending on whether you choose to maximise NMB (cost effectiveness), QALYs (effectiveness), CRC 
incidence reduction or CRC mortality reduction. For example, QALY gains tend to be maximised by 
screening younger ages (as lives saved are associated with a longer life expectancy) whereas CRC 
incidence and mortality tend to see the maximum reductions when screening older ages (as disease 
is more prevalent in older ages). In this report we focus the results on screening strategies which 
optimise cost-effectiveness. 
Outcomes presented are lifetime costs and effects (discounted) for a cohort of 50 year old 
corresponding to the 2016 population of England. Endoscopy use estimates are annual estimates for 
the first year of the new screening strategy for the whole population. The economic results for FIT 
and bowel scope strategies are considered first. Optimal and feasible strategies are then compared, 
including comparison with the existing gFOBT based strategy. Results of sensitivity analyses are 
described here but the tables are provided in the appendix.  
 
6.2 Optimal age for a one of bowel scope or FIT screen 
 
What is the optimal age for a one-off Bowel Scope screen? 
For a one-off bowel scope, 59 was the optimal age to maximise cost effectiveness, see Table 21. The 
maximum QALY gain occurs at age 56, the maximum CRC incidence reduction at age 64/65 and the 
maximum CRC mortality reduction at age 66. A one off bowel scope is associated with both costs 
and QALY gains. Compared to no screening the ICER for a one-off bowel scope at age 59 was 
approximately £3,000 per QALY.  
 
Under the sensitivity analysis which used lower CRC treatment costs the ICER was £8,000 per QALY 
compared to no screening. Under the scenario analysis with higher bowel scope test sensitivity from 
UKFSST, and higher uptake of 55% the ICER was under £2,000 per QALY and the optimal age was 58. 
Under a scenario analysis where the cost of bowel scope was £150 one-off bowel scope was cost 
saving. 
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Table 21: Optimal age for a one-off bowel scope screen
 
 
What is the optimal age for a one-off FIT? Does this vary by FIT threshold? 
For a one-off FIT, 57 was the optimal age to maximise cost effectiveness regardless of FIT threshold, 
see Table 22.  As for a one-off bowel scope the maximum QALY gain occurs at age 56, the maximum 
CRC incidence reduction at age 64/65 and the maximum CRC mortality reduction at age 66. A one-
off FIT was found to be cost saving and therefore dominates the no screening comparison, with cost 
savings ranging from £10m to £35m depending on the FIT threshold. Under the sensitivity analysis 
with lower CRC treatment costs one-off FIT was no longer cost saving and was associated with a cost 
of £3m-£5m and an ICER of about £500/QALY to £1,000/QALY compared to no screening.  
 
Table 22: Optimal age for a one-off FIT screen with FIT120 
 
 Costs 
(£m)  QALYs NMB (£m)
 CRC 
incidence 
 CRC 
mortality 
Bowel Scope age 55 £41.5m 9,654                   £151.5m 7.3% 8.3%
Bowel Scope age 56 £37.1m 9,655                   £156.0m 7.6% 8.7%
Bowel Scope age 57 £33.0m 9,602                   £159.0m 7.9% 9.1%
Bowel Scope age 58 £29.4m 9,497                   £160.6m 8.2% 9.5%
Bowel Scope age 59 £26.2m 9,341                   £160.7m 8.4% 9.8%
Bowel Scope age 60 £22.9m 9,139                   £159.9m 8.6% 10.1%
Bowel Scope age 61 £20.3m 8,892                   £157.5m 8.8% 10.3%
Bowel Scope age 62 £18.0m 8,605                   £154.1m 8.9% 10.5%
Bowel Scope age 63 £16.2m 8,283                   £149.5m 9.0% 10.7%
Bowel Scope age 64 £14.6m 7,928                   £143.9m 9.1% 10.8%
Bowel Scope age 65 £13.4m 7,544                   £137.5m 9.1% 10.9%
Bowel Scope age 66 £12.5m 7,140                   £130.3m 9.1% 11.0%
Bowel Scope age 67 £11.8m 6,716                   £122.5m 9.0% 10.9%
Bowel Scope age 68 £11.3m 6,277                   £114.3m 8.9% 10.8%
Bowel Scope age 69 £11.1m 5,833                   £105.5m 8.7% 10.7%
Bowel Scope age 70 £10.5m 5,385                   £97.2m 8.5% 10.5%
 Screening strategy 
 Incremental compared to no screening Lifetime reduction
 Costs (£m)  QALYs NMB (£m)
 CRC 
incidence 
 CRC 
mortality 
FIT120 age 55 -£12.0m 3,464                   £81.2m 2.4% 2.9%
FIT120 age 56 -£12.5m 3,471                   £81.9m 2.5% 3.1%
FIT120 age 57 -£12.9m 3,459                   £82.1m 2.6% 3.2%
FIT120 age 58 -£13.1m 3,428                   £81.7m 2.7% 3.3%
FIT120 age 59 -£13.3m 3,378                   £80.8m 2.8% 3.4%
FIT120 age 60 -£13.5m 3,310                   £79.7m 2.9% 3.6%
FIT120 age 61 -£13.5m 3,226                   £78.1m 2.9% 3.6%
FIT120 age 62 -£13.4m 3,127                   £76.0m 2.9% 3.7%
FIT120 age 63 -£13.2m 3,013                   £73.5m 3.0% 3.8%
FIT120 age 64 -£12.9m 2,887                   £70.6m 3.0% 3.8%
FIT120 age 65 -£12.5m 2,750                   £67.5m 3.0% 3.9%
FIT120 age 66 -£12.0m 2,605                   £64.1m 3.0% 3.9%
FIT120 age 67 -£11.4m 2,452                   £60.5m 2.9% 3.9%
FIT120 age 68 -£10.8m 2,291                   £56.6m 2.9% 3.9%
FIT120 age 69 -£10.1m 2,128                   £52.6m 2.8% 3.8%
FIT120 age 70 -£9.6m 1,963                   £48.9m 2.7% 3.8%
 Screening strategy 
 Incremental compared to no screening Lifetime reduction
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What is the comparative effectiveness of a one-off bowel scope screen compared to a one-off FIT20 
screen? 
To help the reader understand the relative benefits of bowel scope and FIT, we undertook a 
comparison of one-off bowel scope/FIT20 at optimal ages. When the analysis used uptake rates from 
the BCSP we see that Bowel Scope is the most effective but FIT20 is the most cost effective. 
However, an exploratory analysis in which 100% uptake was assumed for both bowel scope and 
FIT20 illustrates that bowel scope has the potential to be associated with much higher effectiveness 
and cost-effectiveness. Under the scenario analysis with higher bowel scope test sensitivity from 
UKFSST, and higher uptake of 55%, bowel scope was associated with much higher effectiveness and 
cost effectiveness than FIT20. See Table 23 below. 
Table 23: Comparison of a single bowel scope or FIT20 screen at optimal age 
 
 
6.3 Optimising repeated FIT screening 
 
Optimal repeated FIT screening in the absence of endoscopy capacity constraints 
Without endoscopy constraints the optimal FIT screening strategy is the most intensive strategy of 
annual screening with FIT20 ages 50-74. This strategy is cost saving.  
Under the sensitivity analysis in which repeated FIT screens have a lower sensitivity this strategy 
remains cost saving. Under the scenario analysis with loǁĞƌZƚƌĞĂƚŵĞŶƚĐŽƐƚƐ ‘ĂŶŶƵĂů&/d ? ?ĂŐĞƐ
50- ? ? ?ŝƐƐƚŝůůƚŚĞŵŽƐƚĐŽƐƚĞĨĨĞĐƚŝǀĞďƵƚŝƐŶŽůŽŶŐĞƌĐŽƐƚƐĂǀŝŶŐǁŝƚŚĂŶ/ZŽĨũƵƐƚƵŶĚĞƌ ? ? ? ? ? ?
per QALY.  
 
Optimal repeated FIT screening with constrained number of screening referral colonoscopies 
For a fixed screening referral colonoscopy capacity we are interested in the following questions: 
x What is the optimal screening age range 
x What is the optimal screening interval 
 Costs (£m)  QALYs  NMB (£m) 
 CRC 
incidence 
 CRC 
mortality 
Comparison with uptake as observed in the BCSP (BS 44%, FIT 65%)
Bowel Scope age 59 £26.2m 9,341            £160.7m 8.4% 9.8% 9,197                  289,081              
FIT20 age 57 -£35.5m 8,259            £200.7m 6.6% 7.8% 26,333                -                       
Comparison assuming 100% uptake for both Bowel Scope and FIT
Bowel Scope age 59 £55.1m 21,033         £365.6m 19.0% 22.0% 20,708                650,878              
FIT20 age 57 -£56.8m 12,673         £310.2m 10.1% 11.9% 40,405                -                       
Scenario analysis with higher bowel scope test sensitivity from UKFSST, and higher uptake 55%
Bowel Scope age 58 £25.4m 14,286         £260.3m 11.6% 14.0% 13,184                372,511              
 Screening strategy 
 Incremental compared to no screening Lifetime reduction  Screening 
referral 
colonoscopies 
(year 1) 
 Screening 
flexible 
sigmoidoscopy 
(year 1) 
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x For a fixed screening age range, is a higher FIT threshold at a shorter screening interval or a 
lower FIT threshold at longer screening interval preferable? 
x Is it preferable to screen a small age range intensively (short interval, low FIT threshold) or a 
larger age range less intensively. 
Analyses were undertaken comparing screening strategies which had the same screening referral 
colonoscopy requirements. 
 The following range of screening strategies was considered: 
x maximum age range was 50-74 years  
x Screening starting ages between 50 and 60 
x Screening intervals of 1, 2, 3, 4, 5 or 6 years (constant screening interval) 
x 3 or more screening episodes 
x FIT threshold between 20 and 180 (same FIT threshold across all screening ages) 
We note that screening strategies which relax constraints on a constant screening interval and FIT 
threshold will be considered as part of phase 2.  
Results were generated for three screening referral colonoscopy capacities: 50,000 (just over 
estimated current capacity), 70,000 and 90,000 (to reflect optimistic future capacity). Table 24 
presents the 8 most cost effective screening strategies for each of 1-6 yearly screening with 
screening referral colonoscopies <50,0000. 
x With a screening referral colonoscopy capacity of 50,000 (similar to current capacity) the 
optimal strategy was: 2-yearly, age 51-65, FIT161 (8 screening episodes). 
 
x With a screening referral colonoscopy capacity of 70,000 the optimal strategy was: 2-yearly, 
age 50-70, FIT153 (11 screening episodes). 
 
x With a screening referral colonoscopy capacity of 90,000 (to reflect optimistic future 
capacity) the optimal strategy was:  2-yearly, age 50-74, FIT124 (13 screening episodes). 
 
x Results for screening referral colonoscopy capacity over 140,000 suggest that at higher 
capacities annual screening becomes optimal. 
 
For a screening referral colonoscopy capacity of up to 100,000 2-yearly screening was the optimal 
frequency. For higher capacity a lower FIT threshold and wider screening age range is 
recommended. The optimal screening strategies include screening of the 50-59 age group. 
 
Under the scenario analysis in which repeat FIT screens have reduced sensitivity scenario analyses 
suggest that the optimal repeat FIT screening strategy remains unchanged. 
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Table 24: The most cost effective screening strategies with screening referral colonoscopies <50,0000. 
 
 
  
Strategy
Costs (discounted, 
incremental compared 
to no screening)
QALYs (discounted, 
incremental compared 
to no screening)
Cancer 
incidence
Cancer 
mortality
Number 
of 
screens
NMB
 Screening 
referral 
colonoscopys 
Screening referral colonoscopys < 50000
1-yearly, age 56-63, FIT156 -£60.5m 18,372 15.4% 18.9% 8 £427.9m 49,895               
1-yearly, age 55-62, FIT161 -£57.9m 18,464 14.8% 18.1% 8 £427.2m 49,942               
1-yearly, age 56-63, FIT157 -£60.3m 18,333 15.3% 18.8% 8 £427.0m 49,705               
1-yearly, age 55-62, FIT162 -£57.8m 18,426 14.8% 18.0% 8 £426.3m 49,757               
1-yearly, age 57-64, FIT151 -£62.5m 18,187 15.9% 19.6% 8 £426.3m 49,938               
1-yearly, age 56-63, FIT158 -£60.1m 18,295 15.3% 18.8% 8 £426.0m 49,518               
1-yearly, age 55-62, FIT163 -£57.6m 18,389 14.8% 18.0% 8 £425.4m 49,573               
1-yearly, age 57-64, FIT152 -£62.3m 18,148 15.9% 19.6% 8 £425.3m 49,744               
2-yearly, age 51-65, FIT161 -£59.2m 19,098 15.1% 18.4% 8 £441.2m 49,856               
2-yearly, age 53-67, FIT155 -£64.1m 18,824 16.1% 19.9% 8 £440.6m 49,945               
2-yearly, age 51-65, FIT162 -£59.0m 19,056 15.1% 18.4% 8 £440.1m 49,668               
2-yearly, age 52-66, FIT160 -£61.5m 18,915 15.5% 19.1% 8 £439.8m 49,991               
2-yearly, age 53-67, FIT156 -£63.8m 18,780 16.1% 19.8% 8 £439.5m 49,753               
2-yearly, age 51-65, FIT163 -£58.8m 19,014 15.0% 18.3% 8 £439.1m 49,482               
2-yearly, age 52-66, FIT161 -£61.3m 18,872 15.5% 19.0% 8 £438.8m 49,804               
2-yearly, age 53-67, FIT157 -£63.6m 18,737 16.0% 19.8% 8 £438.4m 49,564               
3-yearly, age 52-70, FIT122 -£67.8m 18,274 16.3% 20.3% 7 £433.3m 49,837               
3-yearly, age 50-71, FIT154 -£62.3m 18,539 16.2% 20.2% 8 £433.1m 49,951               
3-yearly, age 50-68, FIT130 -£62.9m 18,485 15.3% 18.9% 7 £432.6m 49,913               
3-yearly, age 50-71, FIT155 -£62.1m 18,493 16.1% 20.2% 8 £431.9m 49,759               
3-yearly, age 52-70, FIT123 -£67.5m 18,218 16.3% 20.2% 7 £431.8m 49,586               
3-yearly, age 50-68, FIT131 -£62.7m 18,431 15.3% 18.8% 7 £431.3m 49,674               
3-yearly, age 52-67, FIT100 -£68.0m 18,157 15.4% 18.9% 6 £431.1m 49,841               
3-yearly, age 50-71, FIT156 -£61.8m 18,447 16.1% 20.1% 8 £430.8m 49,568               
4-yearly, age 50-70, FIT98 -£66.8m 17,933 15.6% 19.3% 6 £425.5m 49,921               
4-yearly, age 51-71, FIT95 -£68.9m 17,807 16.0% 19.9% 6 £425.1m 49,936               
4-yearly, age 50-74, FIT115 -£66.5m 17,886 16.4% 20.7% 7 £424.2m 49,832               
4-yearly, age 50-70, FIT99 -£66.5m 17,861 15.5% 19.2% 6 £423.7m 49,590               
4-yearly, age 51-71, FIT96 -£68.6m 17,734 16.0% 19.8% 6 £423.2m 49,597               
4-yearly, age 50-74, FIT116 -£66.2m 17,825 16.4% 20.7% 7 £422.7m 49,564               
4-yearly, age 50-70, FIT100 -£66.1m 17,791 15.5% 19.1% 6 £421.9m 49,266               
4-yearly, age 51-71, FIT97 -£68.2m 17,662 15.9% 19.7% 6 £421.4m 49,264               
5-yearly, age 50-70, FIT74 -£68.1m 17,379 15.2% 18.7% 5 £415.7m 49,620               
5-yearly, age 51-71, FIT72 -£70.1m 17,239 15.7% 19.3% 5 £414.9m 49,529               
5-yearly, age 50-70, FIT75 -£67.7m 17,284 15.2% 18.6% 5 £413.4m 49,165               
5-yearly, age 51-71, FIT73 -£69.6m 17,143 15.6% 19.2% 5 £412.5m 49,065               
5-yearly, age 50-70, FIT76 -£67.2m 17,192 15.1% 18.5% 5 £411.1m 48,721               
5-yearly, age 51-71, FIT74 -£69.1m 17,048 15.5% 19.1% 5 £410.1m 48,614               
5-yearly, age 52-72, FIT71 -£70.9m 16,937 15.9% 19.8% 5 £409.7m 49,933               
5-yearly, age 50-70, FIT77 -£66.8m 17,101 15.0% 18.5% 5 £408.8m 48,288               
6-yearly, age 50-74, FIT70 -£67.7m 16,646 15.5% 19.4% 5 £400.6m 49,624               
6-yearly, age 52-70, FIT53 -£70.5m 16,496 15.1% 18.6% 4 £400.4m 49,534               
6-yearly, age 53-71, FIT51 -£72.2m 16,364 15.6% 19.2% 4 £399.5m 49,344               
6-yearly, age 50-74, FIT71 -£67.2m 16,548 15.4% 19.3% 5 £398.2m 49,148               
6-yearly, age 52-70, FIT54 -£69.9m 16,369 15.0% 18.4% 4 £397.3m 48,880               
6-yearly, age 53-71, FIT52 -£71.6m 16,233 15.5% 19.0% 4 £396.2m 48,671               
6-yearly, age 50-74, FIT72 -£66.7m 16,452 15.3% 19.2% 5 £395.8m 48,683               
6-yearly, age 50-68, FIT58 -£65.5m 16,472 14.1% 17.1% 4 £394.9m 49,494               
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6.4 Screening strategies combining Bowel scope and FIT 
 
Is it cost effective to replace one screening episode of a repeated FIT strategy with a bowel scope? 
Whether it is cost effective to replace one screening episode of a repeated FIT strategy with a one 
off bowel scope depends upon the screening referral colonoscopy capacity. If we consider the 
replacement of the FIT screen at age 58/9 with a bowel scope then this is cost effective for the 
ƌĞƉĞĂƚĞĚƐƚƌĂƚĞŐǇǁŝƚŚ ? ? ? ? ? ?ƐĐƌĞĞŶŝŶŐƌĞĨĞƌƌĂůĐŽůŽŶŽƐĐŽƉǇĐĂƉĂĐŝƚǇ ‘2-yearly, age 51-65, FIT161 ?, 
but not for the other optimal strategies identified. See Table 25. 
These results varied when sensitivity analyses were run. Under the sensitivity analysis where lower 
CRC treatment costs were used it was not cost effective to replace the FIT screen with bowel scope 
at age 58 in any of the tested strategies. However, under the scenario analysis with higher bowel 
scope test sensitivity from UKFSST, and higher uptake of 55%, it was cost-effective to replace the FIT 
screen at age 58 with bowel scope at any of the screening referral colonoscopy capacity levels 
considered. Under the sensitivity analysis where repeated FIT screens have lower sensitivity it was 
cost-effective to add bowel scope to each of the repeated FIT screening strategies. 
Table 25: Repeated FIT screening with replacement bowel scope 
 
 
For a combination screening strategy with a one off bowel scope followed by FIT screening what is 
the optimal interval between bowel scope and subsequent FIT screening? 
To determine the optimal interval between a bowel scope at age 59 and repeated FIT screening a 
strategy with 4 2-yearly screens following bowel scope was considered (for FIT20 and FIT180). The 
optimal interval between a bowel scope at age 59 and subsequent repeated FIT screening is 1 year 
(i.e. the next FIT screen at age 60). Under the scenario analysis in which data from the UKFSST was 
used to estimate bowel scope test sensitivity and a higher uptake rate of 55% was considered, the 
optimal interval was increased to 3 years with a FIT screen at age 62 being optimal. 
 
 Costs 
(£m)  QALYs  NMB (£m) 
 CRC 
incidence 
 CRC 
mortality 
2-yearly, age 51-65, FIT161
repeated FIT screening -£59.2m 19,098       £441.2m 15.1% 18.4% 49,856               -                      
repeated FIT screen with FIT age 59 replaced by BS -£3.6m 22,373       £451.1m 18.2% 21.7% 52,805               289,081              
2-yearly, age 50-70, FIT153
repeated FIT screening -£73.7m 23,600       £545.8m 20.2% 24.9% 69,912               -                      
repeated FIT screen with FIT age 58 replaced by BS -£12.3m 26,471       £541.7m 22.7% 27.4% 72,438               300,813              
2-yearly, age 50-74, FIT124
repeated FIT screening -£89.7m 27,037       £630.4m 24.7% 30.7% 89,822               -                      
repeated FIT screen with FIT age 58 replaced by BS -£25.7m 29,468       £615.0m 26.9% 32.7% 91,428               300,813              
2-yearly, age 50-74, FIT105
repeated FIT screening -£96.9m 28,486       £666.6m 26.2% 32.2% 99,622               -                      
repeated FIT screen with FIT age 58 replaced by BS -£31.2m 30,627       £643.7m 28.0% 34.0% 100,378             300,813              
 Screening strategy 
 Incremental compared to no 
screening Lifetime reduction
 Screening 
referral 
colonoscopies 
(year1) 
 Screening 
flexible 
sigmoidoscopy 
(year 1) 
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Table 26: Optimal re-invite age for strategies with Bowel Scope 
 
 
6.5 Endoscopy capacity  ? bowel scope versus repeated FIT screening 
A one-off bowel scope at age 59 requires approximately 290k bowel scope procedures and 9k 
screening referral colonoscopies. Based on procedure time one might suggest that 10 bowel scopes 
and 4 screening referral colonoscopies were equivalent. By this equivalence 290k bowel scope could 
be compared to 116k screening referral colonoscopies, hence one-off bowel scope at age 59 is 
associated with 125k screening referral colonoscopies. A repeated FIT screening strategy with 125k 
screening referral colonoscopies would be considerably more effective (over 3 times) and cost 
effective (over 4 times) than a one-off bowel scope at age 59. See Table 27. 
Table 27: Repeated FIT screening and one-off bowel scope with similar  ?total endoscopy capacity ? (assuming 
10 bowel scopes = 4 screening referral colonoscopies) 
  
6.6 gFOBT based strategies 
Table 23 presents the economic results for the key screening strategies.  Biennial gFOBT screening 
from 60-74 years is cost saving and more effective than no screening, addition of a single bowel 
scope at the age of 55 years increases costs and effectiveness and is estimated to be cost effective at 
a threshold of £20,000 per QALY, i.e. increased NMB.  
However all repeated FIT screening strategies have a NMB of over £400 million and are superior to 
the repeated gFOBT strategy with or without bowel scope. The repeated FIT strategies are cost 
saving compared to the gFOBT strategy (and therefore also no screening and gFOBT with bowel 
scope at 55 years) and are more effective than the gFOBT strategies where the FIT threshold is less 
than 160 µg/ml.   
 Costs 
(£m)  QALYs 
 NMB 
(£m) 
 CRC 
incidence 
 CRC 
mortality 
BS age 59, 4 2-yearly FIT20 screens from age 60 -£31.0m 24,488    £520.7m 24.3% 28.7% 103,627                  289,081                  
BS age 59, 4 2-yearly FIT20 screens from age 61 -£34.4m 24,212    £518.7m 24.9% 29.5% 100,259                  289,081                  
BS age 59, 4 2-yearly FIT20 screens from age 62 -£36.8m 23,854    £513.9m 25.3% 30.1% 100,873                  289,081                  
BS age 59, 4 2-yearly FIT20 screens from age 63 -£38.3m 23,428    £506.9m 25.7% 30.6% 100,356                  289,081                  
BS age 59, 4 2-yearly FIT20 screens from age 64 -£39.0m 22,924    £497.5m 25.9% 31.0% 95,414                    289,081                  
BS age 59, 4 2-yearly FIT120 screens from age 60 -£1.8m 17,287    £347.6m 16.4% 19.8% 36,846                    289,081                  
BS age 59, 4 2-yearly FIT120 screens from age 61 -£3.0m 17,146    £346.0m 16.6% 20.2% 36,052                    289,081                  
BS age 59, 4 2-yearly FIT120 screens from age 62 -£3.7m 16,960    £343.0m 16.9% 20.5% 36,805                    289,081                  
BS age 59, 4 2-yearly FIT120 screens from age 63 -£4.0m 16,738    £338.8m 17.0% 20.8% 36,877                    289,081                  
BS age 59, 4 2-yearly FIT120 screens from age 64 -£3.9m 16,472    £333.4m 17.1% 21.0% 35,862                    289,081                  
BS age 59, 4 2-yearly FIT180 screens from age 60 £4.9m 16,072    £316.5m 15.1% 18.2% 31,132                    289,081                  
BS age 59, 4 2-yearly FIT180 screens from age 61 £3.9m 15,954    £315.2m 15.3% 18.6% 30,555                    289,081                  
BS age 59, 4 2-yearly FIT180 screens from age 62 £3.3m 15,797    £312.7m 15.5% 18.9% 31,248                    289,081                  
BS age 59, 4 2-yearly FIT180 screens from age 63 £3.1m 15,610    £309.1m 15.6% 19.1% 31,366                    289,081                  
BS age 59, 4 2-yearly FIT180 screens from age 64 £3.1m 15,385    £304.6m 15.7% 19.3% 30,627                    289,081                  
 Screening flexible 
sigmoidoscopy 
(year 1) 
 Incremental compared to no 
screening Lifetime reduction  Screening referral 
colonoscopies 
(year1) 
 Screening strategy 
Lifetime reduction
 Costs 
(£m)  QALYs  NMB (£m) 
 CRC 
incidence 
 CRC 
mortality 
Bowel Scope age 59 £26.2m 9,341         £160.7m 8.4% 9.8% 9,197                  289,081              
2-yearly, age 50-74, FIT74 -£111.1m 31,613       £743.3m 29.3% 35.6% 125,129             -                      
 Screening strategy 
 Incremental compared to no 
screening 
 Screening 
referral 
colonoscopies 
(year1) 
 Screening 
flexible 
sigmoidoscopy 
(year 1) 
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The following tables presents more detailed results for the key strategies. 
Table 28: Summary results for key screening strategies 
 
Table 29: Cost results for key screening strategies 
 
Table 30: CRC incidence and mortality for key screening strategies 
 
  
 Costs (£m)  QALYs  NMB (£m)  CRC incidence  CRC mortality 
Current £0.0m -             £0.0m -                     -                     -                                   -                                    
gFOBT ages 60-74 biennial -£37.3m 11,608       £269.4m 10.7% 16.8% 36,406                            -                                    
Bowel scope age 55, gFOBT ages 60-74 biennial £12.9m 19,197       £371.1m 16.5% 22.5% 42,920                            329,121                            
One off screens
Bowel Scope age 59 £26.2m 9,341         £160.7m 8.4% 9.8% 9,197                               289,081                            
FIT20 age 57 -£39.6m 9,093         £221.5m 7.3% 8.5% 28,995                            -                                    
Repeated FIT screening
2-yearly, age 51-65, FIT161 -£59.2m 19,098       £441.2m 15.1% 18.4% 49,856                            -                                    
2-yearly, age 50-70, FIT153 -£73.7m 23,600       £545.8m 20.2% 24.9% 69,912                            -                                    
2-yearly, age 50-74, FIT124 -£89.7m 27,037       £630.4m 24.7% 30.7% 89,822                            -                                    
2-yearly, age 50-74, FIT74 -£111.1m 31,613       £743.3m 29.3% 35.6% 125,129                          -                                    
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 -£3.6m 22,373       £451.1m 18.2% 21.7% 52,805                            289,081                            
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 -£12.3m 26,471       £541.7m 22.7% 27.4% 72,438                            300,813                            
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 -£25.7m 29,468       £615.0m 26.9% 32.7% 91,428                            300,813                            
 Screening strategy 
 Incremental compared to no 
screening Lifetime reduction  Screening referral 
colonoscopies (year1) 
 Screening flexible 
sigmoidoscopy (year 1) 
 Cost 
gFOBT/FIT/BS 
Screening 
(discounted) 
 Cost screening 
referral 
colonoscopy/CTC 
(discounted) 
 Total Cost 
Surveillance 
colonoscopy 
(discounted) 
 Cost screening 
complications 
(discounted) 
 Total costs related 
to screening 
(discounted) 
 Cancer 
management (inc. 
pathology) costs 
(discounted) 
 Total cost 
(discounted) 
 Total life 
years gained 
(discounted) 
 Total QALYs 
gained 
(discounted) 
Current
No screening £0.00m £0.00m £0.00m £0.00m £0.00m £846.92m £846.92m 15,225,293   12,214,213   
gFOBT ages 60-74 biennial £10.86m £15.34m £7.66m £0.04m £33.91m £775.73m £809.64m 15,239,965   12,225,821   
Bowel scope age 55, gFOBT ages 60-74 biennial £108.82m £19.05m £13.25m £0.10m £141.22m £718.54m £859.77m 15,248,630   12,233,409   
One-off screens
Bowel Scope age 59 £83.86m £4.90m £6.97m £0.06m £95.79m £777.28m £873.07m 15,236,387   12,223,554   
FIT20 age 57 £4.93m £14.20m £6.39m £0.03m £25.54m £781.77m £807.32m 15,236,041   12,223,306   
Repeated FIT screening
2-yearly, age 51-65, FIT161 £36.55m £22.93m £13.17m £0.06m £72.70m £714.99m £787.69m 15,248,014   12,233,311   
2-yearly, age 50-70, FIT153 £46.79m £30.11m £16.80m £0.07m £93.77m £679.40m £773.17m 15,253,507   12,237,813   
2-yearly, age 50-74, FIT124 £51.30m £37.23m £19.53m £0.09m £108.15m £649.06m £757.21m 15,257,710   12,241,250   
2-yearly, age 50-74, FIT105 £51.48m £50.34m £23.16m £0.11m £125.09m £610.75m £735.84m 15,263,048   12,245,826   
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 £115.08m £23.31m £15.80m £0.10m £154.30m £689.01m £843.31m 15,251,827   12,236,586   
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 £128.53m £30.12m £19.08m £0.12m £177.85m £656.76m £834.61m 15,256,799   12,240,684   
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 £132.98m £36.79m £21.49m £0.13m £191.39m £629.87m £821.26m 15,260,478   12,243,681   
 Screening strategy 
Costs
 Screen 
detected 
CRC 
 Surveillance 
detected 
CRC 
 Symptomatic 
presentation 
CRC 
 Total 
Cancer 
Cases 
 Total 
Cancer 
Deaths 
 CRC 
incidence 
reduction 
 CRC 
mortality 
reduction 
Current
No screening -                 -                 52,015           52,015      22,697      0.0% 0.0%
gFOBT ages 60-74 biennial 4,146            49                  42,239           46,433      18,887      10.7% 16.8%
Bowel scope age 55, gFOBT ages 60-74 biennial 3,936            69                  39,421           43,426      17,579      16.5% 22.5%
One-off screens
Bowel Scope age 59 735                35                  46,860           47,630      20,474      8.4% 9.8%
FIT20 age 57 678                29                  47,527           48,233      20,758      7.3% 8.5%
Repeated FIT screening
2-yearly, age 51-65, FIT161 1,899            62                  42,199           44,159      18,514      15.1% 18.4%
2-yearly, age 50-70, FIT153 2,865            84                  38,581           41,530      17,049      20.2% 24.9%
2-yearly, age 50-74, FIT124 3,826            99                  35,224           39,149      15,732      24.7% 30.7%
2-yearly, age 50-74, FIT105 4,004            116                32,679           36,799      14,628      29.3% 35.6%
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 1,956            74                  40,499           42,529      17,760      18.2% 21.7%
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 2,783            94                  37,326           40,202      16,472      22.7% 27.4%
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 3,689            107                34,244           38,039      15,269      26.9% 32.7%
Cancer Incidence and mortality
 Screening strategy 
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Table 31: Screening results for key screening strategies 
 
Table 32: Endoscopy resource use for key screening strategies  
*Note that estimated surveillance colonoscopies are presented for year 5 rather than year 1 as it takes several 
years for the new screening strategy to result in a change in surveillance colonoscopies. However, annual 
screening referral colonoscopies and bowel scope resource use is similar over years 1-5. 
 Invited for 
screening 
 Screening 
responders 
 Endoscopy 
harm: 
bleeds 
 Endoscopy 
harm: 
perforations 
Current
No screening -                  -                  -              -                  
gFOBT ages 60-74 biennial 5,491,540        3,402,152        18               48                   
Bowel scope age 55, gFOBT ages 60-74 biennial 6,262,691        3,745,030        125             64                   
One-off screens
Bowel Scope age 59 753,581           334,696           107             25                   
FIT20 age 57 762,675           497,041           13               26                   
Repeated FIT screening
2-yearly, age 51-65, FIT161 5,995,975        3,898,626        20               54                   
2-yearly, age 50-70, FIT153 8,080,851        5,253,562        28               74                   
2-yearly, age 50-74, FIT124 9,323,799        6,060,855        36               93                   
2-yearly, age 50-74, FIT105 9,313,358        6,051,502        49               113                 
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 5,985,014        3,734,148        122             63                   
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 8,072,293        5,090,197        130             82                   
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 9,318,847        5,900,870        138             99                   
Screening
 Screening strategy 
Harm
 Screening referral 
colonoscopies 
(year1) 
 Screening flexible 
sigmoidoscopy 
(year 1) 
 Surveillance 
Endoscopy 
Utilisation (year 5) 
 CTC 
Usage 
(year 1) 
Current
No screening -                       -                      -                     -        
gFOBT ages 60-74 biennial 36,406                 -                      21,264                1,637     
Bowel scope age 55, gFOBT ages 60-74 biennial 42,920                 329,121               32,746                1,824     
One-off screens
Bowel Scope age 59 9,197                   289,081               21,264                291        
FIT20 age 57 28,995                 -                      21,264                884        
Repeated FIT screening
2-yearly, age 51-65, FIT161 49,856                 -                      21,264                1,623     
2-yearly, age 50-70, FIT153 69,912                 -                      21,264                2,520     
2-yearly, age 50-74, FIT124 89,822                 -                      21,264                3,468     
2-yearly, age 50-74, FIT105 125,129                -                      21,264                4,793     
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 52,805                 289,081               21,264                1,723     
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 72,438                 300,813               21,264                2,608     
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 91,428                 300,813               21,264                3,527     
 Screening strategy 
 Annual endoscopoy resource use    (for the entire 2016 population) 
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Table 33: Detailed cost effectiveness results for key screening strategies
 
  
Incrementals compared to no screening
 Total costs 
related to 
screening 
(discounted) 
 Cancer 
management (inc. 
pathology) costs 
(discounted) 
 Total cost 
(discounted) 
 Total life 
years gained 
(discounted) 
 Total QALYs 
gained 
(discounted) 
 NMB 
Current
No screening £0.0m £0.0m £0.0m -                -                £0.0m
gFOBT ages 60-74 biennial £33.9m -£71.2m -£37.3m 14,672          11,608          £269.4m
Bowel scope age 55, gFOBT ages 60-74 biennial £141.2m -£128.4m £12.9m 23,337          19,197          £371.1m
One-off screens
Bowel Scope age 59 £95.8m -£69.6m £26.2m 11,094          9,341            £160.7m
FIT20 age 57 £25.5m -£65.1m -£39.6m 10,748          9,093            £221.5m
Repeated FIT screening
2-yearly, age 51-65, FIT161 £72.7m -£131.9m -£59.2m 22,720          19,098          £441.2m
2-yearly, age 50-70, FIT153 £93.8m -£167.5m -£73.7m 28,214          23,600          £545.8m
2-yearly, age 50-74, FIT124 £108.2m -£197.9m -£89.7m 32,416          27,037          £630.4m
2-yearly, age 50-74, FIT105 £125.1m -£236.2m -£111.1m 37,754          31,613          £743.3m
Bowel scope and repeated FIT screening
Bowel scope age 59, 2-yearly, age 51-65 (excl.59), FIT161 £154.3m -£157.9m -£3.6m 26,534          22,373          £451.1m
Bowel scope age 58, 2-yearly, age 50-70 (excl. 58), FIT153 £177.9m -£190.2m -£12.3m 31,506          26,471          £541.7m
Bowel scope age 58, 2-yearly, age 50-74 (excl. 58), FIT124 £191.4m -£217.0m -£25.7m 35,185          29,468          £615.0m
 Screening strategy 
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6.7 Results summary 
 
Optimal age of one-off bowel scope or FIT screen 
The optimal age (in terms of cost-effectiveness) for a one-off bowel scope screen is 59. (Note that 
QALY gain is optimised at a younger age and incidence and mortality reduction is maximised at an 
older age.) 
The optimal age (in terms of cost-effectiveness) for a one-off FIT120 screen is 57 regardless of FIT 
threshold (all thresholds between 20-180 µg/ml were considered). 
Comparing a one-off FIT20 and a one of bowel scope, we see that bowel scope is the most effective 
but FIT20 is the most cost effective. However under analyses in which bowel scope uptake and/or 
effectiveness is increased, bowel scope was associated with much higher effectiveness and cost 
effectiveness than FIT20 
Optimising repeated FIT screening 
With no constraints on the number of screening referral colonoscopies the optimal strategy is: FIT20 
annual ages 50-74. 
The optimal screening age range, screening interval, and FIT threshold depend on the screening 
referral colonoscopy capacity. For a screening referral colonoscopy capacity of 50,000 (current)-
90,000(optimistic future) 2-yearly screening from age 50/51 is optimal. For higher levels of screening 
referral colonoscopy capacity screening with a lower FIT threshold and a wider age range is optimal.  
Screening referral colonoscopy capacity Optimal repeated FIT screening strategy 
50,000 (similar to current capacity) 2-yearly, age 51-65, FIT161 (8 screens) 
70000 2-yearly, age 50-70, FIT153 (11 screens) 
90,000 (optimistic future capacity) 2-yearly, age 50-74, FIT124 (13 screens) 
110,000  2-yearly, age 50-74, FIT90 (13 screens) 
130,000  2-yearly, age 50-74, FIT70 (13 screens) 
150,000  1-yearly, age 50-74, FIT159 (25 screens) 
 
Screening strategies combining Bowel scope and FIT 
It is cost effective to replace FIT screening with one-off bowel scope at age 58 in the optimal 
repeated FIT screening strategy identified at a capacity of 50,000 screening referral colonoscopies, 
but not at higher screening referral colonoscopy capacity levels. However, this conclusion varied 
when scenario analyses were run. 
Endoscopy capacity  ? bowel scope versus repeated FIT screening 
We consider an assumption that 10 bowel scopes and 4 screening referral colonoscopies are 
equivalent (based on procedure time). A repeated FIT screening strategy with 125k screening 
referral colonoscopies would be considerably more effective (over 3 times) and cost effective (over 4 
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times) than a one-off bowel scope at age 59 (290k bowel scopes, 9k screening referral 
colonoscopies)  
.
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6.8 Endoscopy capacity in years 1-20 
Model predictions for expected resource use were generated considering changing from gFOBT 60-74 2-yearly 
to the proposed screening strategy. Resource use will change over time due to (1) more rounds of the 
proposed screening strategy being completed (lower disease prevalence and more persons undergoing 
surveillance); and (2) the changing age distribution over time e.g. 55 year olds in future years than in 2016. 
 
The required endoscopy requirements for the first five years are detailed in Table 34 and Figure 21. Screening 
referral colonoscopy capacity is similar over the first 6 years and then decreases subsequently as disease 
prevalence in the population decreases. This decrease more marked for screening strategy using a more 
sensitive test.  
 
Surveillance colonoscopy capacity estimates are subject to considerable uncertainty as explored in the model 
validation section. However, current estimates suggest that surveillance colonoscopy capacity will increase 
over the first 8 years before then decreasing. Increases in years 2 and 4 are related to the fact that there will 
be no new surveillance in year 1 and more in years 2 and 4 (for annual and 3-yearly recall). 
 
Table 34: Required capacity (screening referral colonoscopies) over the first 20 years 
 
Figure 21: Screening referral colonoscopy utilisation following introduction of new screening strategy
  
1 2 3 4 5 6 8 10 15 20
2-yearly, age 51-65, FIT161
Screening referral colonoscopy 49,856 51,316 50,015 51,108 50,300 50,963 44,548 38,203 25,534 6,062
Surveillance colonoscopy 21,264 22,967 23,690 27,306 29,186 28,819 34,551 35,223 29,653 20,191
Total 71,120 74,283 73,705 78,414 79,486 79,782 79,099 73,426 55,187 26,253
2-yearly, age 50-70, FIT153
Screening referral colonoscopy 69,912 71,658 69,437 69,688 68,362 69,125 62,525 56,293 37,567 25,218
Surveillance colonoscopy 21,264 24,744 25,751 33,551 36,667 36,217 46,169 46,520 41,081 31,167
Total 91,176 96,402 95,188 103,239 105,029 105,342 108,694 102,813 78,648 56,385
2-yearly, age 50-74, FIT124
Screening referral colonoscopy 89,822 92,209 89,446 91,254 88,713 90,636 81,279 73,545 52,550 40,102
Surveillance colonoscopy 21,264 26,408 27,764 39,404 44,099 43,420 56,819 57,127 49,744 39,145
Total 111,086 118,617 117,210 130,658 132,812 134,057 138,098 130,673 102,294 79,247
2-yearly, age 50-74, FIT105
Screening referral colonoscopy 99,622 102,247 98,811 100,790 97,748 99,847 89,199 80,450 57,019 43,314
Surveillance colonoscopy 21,264 27,070 28,561 41,672 46,938 45,949 60,895 60,982 52,554 41,114
Total 120,885 129,317 127,372 142,462 144,687 145,796 150,094 141,432 109,573 84,428
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6.9 Other Sensitivity Analyses 
Cost of bowel scope 
Discount rate 
As expected, when discount rates are reduced, more costs and QALYs are produced with each screening 
strategy. Given that disproportionately more QALYs are produced in the future, which is subject to higher 
discounting, the reduction in discount rate reduces the ICER of the optimal strategy for each of the three 
capacity scenarios. There is no change in the optimal strategy amongst strategies tested. 
Colorectal cancer natural history model 
Increasing symptomatic presentation rates increases total costs and QALYs for all strategies, but has very little 
effect on the ICER, meaning that optimal strategies remain the same as in the base case. 
Population gender subgroups  
Total costs are estimated to be higher in males than in females, because of increased treatment costs due to 
higher CRC incidence rate in males. Similarly, total QALYs gained are lower in males than females. However, 
ICERs are much higher in women than men as incremental QALYs are much lower in females, as they have less 
capacity to benefit from screening.  
Probabilistic sensitivity analysis 
Results are provided in the appendix. 
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7 Conclusion 
7.1 Policy implications of findings 
 
Repeated FIT screening  
1. Regardless of capacity constraints the current screening strategies (gFOBT 2-yearly 60-74 with or 
without bowel scope age 55) are dominated by a FIT screening strategy (i.e. a FIT strategy exists which 
is more effective and less expensive). 
2. The optimal age for a repeated FIT screening strategy is 50/51 hence it is suggested that the screening 
start age is reduced compared to what is currently used in the BCSP. The upper screening age varies 
between 65 and 74, depending on the capacity constraint used.  
3. It is recommended that the screening interval is kept to 2-yearly screening. However, increased 
benefits may be obtained my re-inviting non-attenders after a 1 year interval. 
4. The optimal FIT threshold depends on the available capacity for screening referral colonoscopies: 
x With 50,000 screening referral colonoscopies (current capacity) then we recommend a strategy 
of 2-yearly, age 51-65, FIT161 (8 screens).  
x If 90,000 screening referral colonoscopies is considered feasible to achieve in the future then we 
recommend a strategy of 2-yearly, age 50-74, FIT124 (13 screens). 
Note that these conclusions are based on optimising cost-effectiveness. If the aim was to optimise QALY gains 
or CRC incidence/mortality reduction then conclusions would be different. 
 
Bowel Scope screening 
1. There is some uncertainty in whether it is cost effective to replace one FIT screen with a one-
off bowel scope at age 58/59.  
2. A repeated FIT screening strategy with 125k screening referral colonoscopies would be 
considerably more effective (over 3 times) and cost effective (over 4 times) than a one-off 
bowel scope at age 59 (290k bowel scopes, 9k screening referral colonoscopies).Such 
strategies could be considered to have equivalent  ‘endoscopy capacity ? ?ĂƐƐƵŵŝŶŐƚŚĂƚ10 
bowel scopes and 4 screening referral colonoscopies are equivalent). 
3. Hence, if bowel scope capacity could be used for undertaking screening referral 
colonoscopies this would result in higher cost-effectiveness. 
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7.2 Limitations of the analysis and future research 
 
FIT CRC sensitivity data 
There is a very large degree of uncertainty in the sensitivity to cancer of FIT due to the small sample size. 
However, the FIT pilot data reflects usage of FIT in a (non-trial) screening setting so we suggest it is the most 
appropriate data source for this analysis. The result of this is increased uncertainty in model predictions 
involving FIT. 
Variations in CRC risk and screening uptake within the population 
The approach taken here models the whole population as a series of homogenous age cohorts. As it is known 
that screening attendance can be lower in some subgroups with higher CRC risk (e.g. males) this cohort 
modelling approach will not accurately estimate the cost effectiveness of screening. This inaccuracy is however 
unlikely to impact on the incremental cost-effectiveness of different screening strategies. Phase 1 started to 
look at the differential cost  ?effectiveness in different population subgroups by considering males and females 
separately.  This limitation will be addressed within the patient level model structure proposed in Phase 2. 
Phase 2 will aim to deliver a patient level model structure that is compatible with addressing anticipated future 
research questions. This will include the evaluation of targeted screening uptake interventions, and patient 
level screening strategies. 
Uncertainty in surveillance model predictions 
There is a high degree of uncertainty in the data which informs the surveillance component of the screening 
model. Data was not available to refine or properly validate this component of the model for this phase. 
Validation analyses demonstrated that the surveillance model parameters (such as adenoma recurrence rates 
following polypectomy) have a large impact on model predicted cancer rates. This uncertainty translates 
directly to uncertainty in model predictions and conclusions. As a result of the differences between the 
ScHARR model predictions and BCSP data the model predicted surveillance colonoscopy estimates presented 
here should be treated with caution. 
As part of phase 2 it is proposed that (1) further data will be obtained to inform the surveillance component of 
the model and (2) the patient level model structure will allow evaluation of alternative surveillance criteria 
including FIT for follow up and alternative stopping criteria. 
Screening strategies combining bowel scope and FIT 
There is considerable uncertainty in how different screening modalities with work when used in combination. 
This is due to the lack of trial evidence to inform this part of the model. Hence the predictions in relation to 
combination screening strategies which include bowel scope and FIT should be treated with caution.  
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